BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saltz LB, Clarke S, Díaz-rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. JCO 2008;26:2013-9. [DOI: 10.1200/jco.2007.14.9930] [Cited by in Crossref: 2022] [Cited by in F6Publishing: 899] [Article Influence: 144.4] [Reference Citation Analysis]
Number Citing Articles
1 Agostara B, Carruba G, Usset A. The management of cancer in the elderly: targeted therapies in oncology. Immun Ageing 2008;5:16. [PMID: 19116012 DOI: 10.1186/1742-4933-5-16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
2 Garrido I, Hidalgo M. Complete tumor response after folfox and bevacizumab chemotherapy in a patient with advanced colorectal cancer: . Anti-Cancer Drugs 2009;20:S37-9. [DOI: 10.1097/01.cad.0000359487.76411.8d] [Reference Citation Analysis]
3 Baba H, Yamada Y, Takahari D, Matsumoto H, Yoshida K, Nakamura M, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. ESMO Open 2017;2:e000135. [PMID: 28761727 DOI: 10.1136/esmoopen-2016-000135] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zdenkowski N, Chen S, van der Westhuizen A, Ackland S. Curative strategies for liver metastases from colorectal cancer: a review. Oncologist. 2012;17:201-211. [PMID: 22234631 DOI: 10.1634/theoncologist.2011-0300] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
5 Gordan L, Grogg A, Blazer M, Fortner B. Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed? J Oncol Pract 2017;13:e139-51. [PMID: 28029298 DOI: 10.1200/JOP.2016.016550] [Reference Citation Analysis]
6 Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012;2:a006577. [PMID: 23028128 DOI: 10.1101/cshperspect.a006577] [Cited by in Crossref: 132] [Cited by in F6Publishing: 124] [Article Influence: 13.2] [Reference Citation Analysis]
7 Chow FCL, Chok KSH. Colorectal liver metastases: An update on multidisciplinary approach. World J Hepatol 2019; 11(2): 150-172 [PMID: 30820266 DOI: 10.4254/wjh.v11.i2.150] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 20.7] [Reference Citation Analysis]
8 Meadows KL, Rushing C, Honeycutt W, Latta K, Howard L, Arrowood CA, Niedzwiecki D, Hurwitz HI. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. Support Care Cancer 2015;23:1311-9. [PMID: 25341548 DOI: 10.1007/s00520-014-2465-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
9 Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal. Pharmacoeconomics 2012;30:1119-32. [PMID: 23058097 DOI: 10.2165/11597210-000000000-00000] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
10 Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Target Oncol. 2017;12:599-610. [PMID: 28801849 DOI: 10.1007/s11523-017-0518-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 11.5] [Reference Citation Analysis]
11 Sun LM, Lin CL, Lin MC, Liang JA, Kao CH. Radiotherapy- and chemotherapy-induced myelodysplasia syndrome: a nationwide population-based nested case-control study. Medicine (Baltimore) 2015;94:e737. [PMID: 25929909 DOI: 10.1097/MD.0000000000000737] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
12 Koch C, Schwing AM, Herrmann E, Borner M, Diaz-Rubio E, Dotan E, Feliu J, Okita N, Souglakos J, Arkenau HT, Porschen R, Koopman M, Punt CJA, de Gramont A, Tournigand C, Zeuzem S, Trojan J. Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis. Oncotarget 2018;9:10272-83. [PMID: 29535805 DOI: 10.18632/oncotarget.23475] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
13 Spencer SK, Pommier AJ, Morgan SR, Barry ST, Robertson JD, Hoff PM, Jürgensmeier JM. Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy. Br J Cancer. 2013;109:2765-2773. [PMID: 24149180 DOI: 10.1038/bjc.2013.649] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
14 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Hashiguchi T, Nakatani A, Marusasa T, Muraki A, Nagaoka I, Futagawa S. Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test. Exp Ther Med 2010;1:325-9. [PMID: 22993545 DOI: 10.3892/etm_00000050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
15 Heijmen L, Punt CJ, Ter Voert EG, de Geus-Oei LF, Heerschap A, Bussink J, Sweep CG, Zerbi V, Oyen WJ, Span PN, Boerman O, van Laarhoven HW. Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach. Invest New Drugs 2013;31:881-90. [PMID: 23325291 DOI: 10.1007/s10637-012-9920-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
16 Koilakou S, Petrou P. Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review. Mol Diagn Ther 2021;25:715-34. [PMID: 34816395 DOI: 10.1007/s40291-021-00560-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15:106-115. [PMID: 23297721 DOI: 10.1111/j.1477-2574.2012.00558] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Reese ES, Onukwugha E, Hanna N, Seal BS, Mullins CD. Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients. Cancer Med 2013;2:907-15. [PMID: 24403264 DOI: 10.1002/cam4.143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
19 Dewdney A, Cunningham D, Barbachano Y, Chau I. Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. Br J Cancer. 2012;106:1718-1721. [PMID: 22531628 DOI: 10.1038/bjc.2012.152] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
20 Cho H, Kim JE, Kim KP, Yu CS, Kim JC, Kim JH, Lee MA, Jang HS, Oh ST, Kim SY, Oh JH, Kim DY, Hong YS, Kim TW. Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases. Am J Clin Oncol 2016;39:623-9. [PMID: 27322695 DOI: 10.1097/COC.0000000000000315] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
21 Malik PS, Raina V, André N. Metronomics as maintenance treatment in oncology: time for chemo-switch. Front Oncol 2014;4:76. [PMID: 24782987 DOI: 10.3389/fonc.2014.00076] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
22 Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 2017;20:185-204. [PMID: 28361267 DOI: 10.1007/s10456-017-9552-y] [Cited by in Crossref: 215] [Cited by in F6Publishing: 220] [Article Influence: 43.0] [Reference Citation Analysis]
23 Xu J, Qin X, Wang J, Zhang S, Zhong Y, Ren L, Wei Y, Zeng S, Wan D, Zheng S; Society of Surgery; Chinese Medical Association; Committee of Colorectal Cancer, Chinese Anti-cancer Association. Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol. 2011;137:1379-1396. [PMID: 21796415 DOI: 10.1007/s00432-011-0999-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
24 Govaert KM, van Kessel CS, Lolkema M, Ruers TJ, Borel Rinkes IH. Does Radiofrequency Ablation Add to Chemotherapy for Unresectable Liver Metastases? Curr Colorectal Cancer Rep. 2012;8:130-137. [PMID: 22611343 DOI: 10.1007/s11888-012-0122-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
25 Javle M, Smyth EC, Chau I. Ramucirumab: successfully targeting angiogenesis in gastric cancer. Clin Cancer Res 2014;20:5875-81. [PMID: 25281695 DOI: 10.1158/1078-0432.CCR-14-1071] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 5.1] [Reference Citation Analysis]
26 Parmar MK, Barthel FM, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart AM, Qian W, Royston P. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 2008;100:1204-14. [PMID: 18728279 DOI: 10.1093/jnci/djn267] [Cited by in Crossref: 93] [Cited by in F6Publishing: 78] [Article Influence: 6.6] [Reference Citation Analysis]
27 Dionísio de Sousa IJ, Ferreira J, Rodrigues J, Bonito N, Jacinto P, Marques M, Ribeiro J, Pais A, Gervásio H. Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer. ESMO Open 2016;1:e000045. [PMID: 27843607 DOI: 10.1136/esmoopen-2016-000045] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
28 Moriarity A, O'Sullivan J, Kennedy J, Mehigan B, McCormick P. Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:276-293. [PMID: 27482287 DOI: 10.1177/1758834016646734] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 9.0] [Reference Citation Analysis]
29 Chen YX, Yang Q, Kuang JJ, Chen SY, Wei Y, Jiang ZM, Xie DR. Efficacy of adding bevacizumab in the first-line chemotherapy of metastatic colorectal cancer: evidence from seven randomized clinical trials. Gastroenterol Res Pract 2014;2014:594930. [PMID: 24971091 DOI: 10.1155/2014/594930] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
30 Cohn AL, Yoshino T, Heinemann V, Obermannova R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia-Alfonso P, Portnoy DC, Van Cutsem E, Yamazaki K, Clingan PR, Polikoff J, Lonardi S, O'Brien LM, Gao L, Yang L, Ferry D, Nasroulah F, Tabernero J. Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. Cancer Chemother Pharmacol 2017;80:599-608. [PMID: 28744667 DOI: 10.1007/s00280-017-3380-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
31 Kubo A, Hashimoto H, Takahashi N, Yamada Y. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. World J Gastroenterol 2016; 22(2): 887-894 [PMID: 26811634 DOI: 10.3748/wjg.v22.i2.887] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
32 Lin CY, Lin TH, Chen CC, Chen MC, Chen CP. Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study. PLoS One 2018;13:e0190497. [PMID: 29304109 DOI: 10.1371/journal.pone.0190497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
33 Lubner SJ, Loconte NK, Holen KD, Schelman W, Thomas JP, Jumonville A, Eickhoff JC, Seo S, Mulkerin DL. A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2010;9:157-161. [PMID: 20643620 DOI: 10.3816/ccc.2010.n.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
34 Yin C, Ma G, Rong Y, Kong P, Yang Q, Jiang C, Liao F, Zhang B, He W, Xia L. The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer. J Cancer 2016;7:1901-6. [PMID: 27698931 DOI: 10.7150/jca.15802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
35 Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H, Uchida J, Matsuo K, Takechi T. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep 2015;33:2135-42. [PMID: 25812794 DOI: 10.3892/or.2015.3876] [Cited by in Crossref: 6] [Cited by in F6Publishing: 22] [Article Influence: 0.9] [Reference Citation Analysis]
36 Shiroiwa T, Fukuda T, Tsutani K. Health utility scores of colorectal cancer based on societal preference in Japan. Qual Life Res 2009;18:1095-103. [PMID: 19626462 DOI: 10.1007/s11136-009-9513-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
37 Song X, Long SR, Barber B, Kassed CA, Healey M, Jones C, Zhao Z. Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer. Curr Clin Pharmacol 2012;7:56-65. [PMID: 22299770 DOI: 10.2174/157488412799218806] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
38 Miyazawa T, Ebe K, Koide N, Fujita N. Complete Response of Isolated Para-aortic Lymph Node Recurrence from Rectosigmoid Cancer Treated by Chemoradiation Therapy with Capecitabine/Oxaliplatin plus Bevacizumab: A Case Report. Case Rep Oncol 2012;5:216-21. [PMID: 22679426 DOI: 10.1159/000338840] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
39 Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? Oncotarget 2016;7:9309-21. [PMID: 26824184 DOI: 10.18632/oncotarget.7008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
40 Maor Y, Malnick S. Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol. 2013;2013:815105. [PMID: 23970972 DOI: 10.1155/2013/815105] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
41 Shibutani M, Maeda K, Nagahara H, Ohtani H, Iseki Y, Ikeya T, Sugano K, Hirakawa K. The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer. BMC Cancer 2015;15:347. [PMID: 25934494 DOI: 10.1186/s12885-015-1375-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
42 Koukourakis GV, Sotiropoulou-Lontou A. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clin Transl Oncol 2011;13:710-4. [PMID: 21975331 DOI: 10.1007/s12094-011-0720-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
43 López-Gómez M, Merino M, Casado E. Long-term treatment of metastatic colorectal cancer with panitumumab. Clin Med Insights Oncol 2012;6:125-35. [PMID: 22408376 DOI: 10.4137/CMO.S5055] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
44 Shitara K. RAINFALL before RAINBOW-an illusion or reality? Transl Gastroenterol Hepatol 2017;2:26. [PMID: 28447061 DOI: 10.21037/tgh.2017.03.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
45 Parikh RC, Du XL, Morgan RO, Lairson DR. Patterns of Treatment Sequences in Chemotherapy and Targeted Biologics for Metastatic Colorectal Cancer: Findings from a Large Community-Based Cohort of Elderly Patients. Drugs Real World Outcomes 2016;3:69-82. [PMID: 27747803 DOI: 10.1007/s40801-015-0059-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
46 Spurrell EL, Lockley M. Adaptive immunity in cancer immunology and therapeutics. Ecancermedicalscience 2014;8:441. [PMID: 25075215 DOI: 10.3332/ecancer.2014.441] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
47 Folprecht G, Bechstein WO. [Neoadjuvant therapy concepts for liver metastases]. Chirurg. 2011;82:989-994. [PMID: 22033894 DOI: 10.1007/s00104-011-2131-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
48 Hochster HS. HORIZON I: Is there a future for oral anti-angiogenics on the horizon of colorectal cancer therapy? Br J Cancer 2013;108:477-8. [PMID: 23422787 DOI: 10.1038/bjc.2013.20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
49 Marshall JL. Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism? J Oncol 2009;2009:937305. [PMID: 20016807 DOI: 10.1155/2009/937305] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
50 Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer. 2014;14:897. [PMID: 25487708 DOI: 10.1186/1471-2407-14-897] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
51 Fenocchio E, Colombi F, Calella MG, Filippi R, Depetris I, Chilà G, Lombardi P, Marino D, Cagnazzo C, Ferraris R, Vaira M, Aglietta M, Leone F. Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience. Cancers (Basel) 2019;11:E369. [PMID: 30884763 DOI: 10.3390/cancers11030369] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
52 Modest DP, Rivera F, Bachet JB, de Braud F, Pietrantonio F, Koukakis R, Demonty G, Douillard JY. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. Int J Cancer 2019;145:576-85. [PMID: 30614531 DOI: 10.1002/ijc.32110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
53 Wu C, Wang X, Tomko N, Zhu J, Wang WR, Zhu J, Wangf B, Wang Y, Salomon RG. 2-(ω-Carboxyethyl)pyrrole Antibody as a New Inhibitor of Tumor Angiogenesis and Growth. Anticancer Agents Med Chem 2017;17:813-20. [PMID: 27671308 DOI: 10.2174/1871520616666160923093959] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
54 Elez E, Argilés G, Tabernero J. First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405. Curr Treat Options Oncol. 2015;16:52. [PMID: 26374340 DOI: 10.1007/s11864-015-0369-x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
55 Zhang B, Fang C, Deng D, Xia L. Research progress on common adverse events caused by targeted therapy for colorectal cancer. Oncol Lett 2018;16:27-33. [PMID: 29928383 DOI: 10.3892/ol.2018.8651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
56 Vadakara J, Borghaei H. Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med 2012;5:113-23. [PMID: 23226067 DOI: 10.2147/PGPM.S24258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 14] [Article Influence: 0.1] [Reference Citation Analysis]
57 Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Tabernero J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist. 2013;18:1004-1012. [PMID: 23881988 DOI: 10.1634/theoncologist.2013-0107] [Cited by in Crossref: 155] [Cited by in F6Publishing: 142] [Article Influence: 17.2] [Reference Citation Analysis]
58 Volz NB, Stintzing S, Zhang W, Yang D, Ning Y, Wakatsuki T, El-Khoueiry RE, Li JE, Kardosh A, Loupakis F, Cremolini C, Falcone A, Scherer SJ, Lenz HJ. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics J 2015;15:69-76. [PMID: 25069475 DOI: 10.1038/tpj.2014.40] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
59 Stein A, Rüssel J, Peinert S, Arnold D. The role of peri-operative treatment in resectable liver metastases of colorectal cancer. Ther Adv Med Oncol 2010;2:389-98. [PMID: 21789150 DOI: 10.1177/1758834010375095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
60 Mitani S, Muro K. No benefit from ramucirumab in first-line chemotherapy? Transl Gastroenterol Hepatol 2017;2:30. [PMID: 28529984 DOI: 10.21037/tgh.2017.03.18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
61 Mahmood RD, Shaw D, Descamps T, Zhou C, Morgan RD, Mullamitha S, Saunders M, Mescallado N, Backen A, Morris K, Little RA, Cheung S, Watson Y, O'Connor JPB, Jackson A, Parker GJM, Dive C, Jayson GC. Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study. BMC Cancer 2021;21:354. [PMID: 33794823 DOI: 10.1186/s12885-021-08097-9] [Reference Citation Analysis]
62 Xu RH, Li J, Bai Y, Xu J, Liu T, Shen L, Wang L, Pan H, Cao J, Zhang D, Fan S, Hua Y, Su W. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol 2017;10:22. [PMID: 28103904 DOI: 10.1186/s13045-016-0384-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
63 Vogel A, Kirstein MM. First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials. Innov Surg Sci 2018;3:85-6. [PMID: 31579770 DOI: 10.1515/iss-2018-0012] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
64 Sugihara K, Ohtsu A, Shimada Y, Mizunuma N, Gomi K, Lee PH, Gramont A, Rothenberg ML, André T, Brienza S, Goldberg RM. Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. Cancer Med 2012;1:198-206. [PMID: 23342269 DOI: 10.1002/cam4.25] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
65 Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P, Xynogalos S, Christophyllakis Ch, Kouroussis Ch, Vamvakas L. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). Br J Cancer. 2012;106:453-459. [PMID: 22240792 DOI: 10.1038/bjc.2011.594] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
66 Jin KT, Chen B, Liu YY, Lan HU, Yan JP. Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. Cancer Cell Int 2021;21:83. [PMID: 33522929 DOI: 10.1186/s12935-021-01763-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Bennouna J, Deslandres M, Senellart H, de Labareyre C, Ruiz-Soto R, Wixon C, Botbyl J, Suttle AB, Delord JP. A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. Invest New Drugs 2015;33:138-47. [PMID: 25248752 DOI: 10.1007/s10637-014-0142-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
68 Oki E, Ando K, Nakanishi R, Sugiyama M, Nakashima Y, Kubo N, Kudou K, Saeki H, Nozoe T, Emi Y, Maehara Y. Recent advances in treatment for colorectal liver metastasis. Ann Gastroenterol Surg 2018;2:167-75. [PMID: 29863162 DOI: 10.1002/ags3.12071] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
69 Mack JW, Cronin A, Taback N, Huskamp HA, Keating NL, Malin JL, Earle CC, Weeks JC. End-of-life care discussions among patients with advanced cancer: a cohort study. Ann Intern Med 2012;156:204-10. [PMID: 22312140 DOI: 10.7326/0003-4819-156-3-201202070-00008] [Cited by in Crossref: 238] [Cited by in F6Publishing: 200] [Article Influence: 23.8] [Reference Citation Analysis]
70 Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1-42. [PMID: 31203527 DOI: 10.1007/s10147-019-01485-z] [Cited by in Crossref: 282] [Cited by in F6Publishing: 260] [Article Influence: 94.0] [Reference Citation Analysis]
71 de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2010;28:460-465. [PMID: 20008641 DOI: 10.1200/jco.2009.23.1407] [Cited by in Crossref: 50] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
72 Hong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, Park SH, Kim SY, Baek JY, Kim JH. Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy. Invest New Drugs. 2013;31:183-191. [PMID: 22782485 DOI: 10.1007/s10637-012-9853-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
73 Babae N, Bourajjaj M, Liu Y, Van Beijnum JR, Cerisoli F, Scaria PV, Verheul M, Van Berkel MP, Pieters EH, Van Haastert RJ, Yousefi A, Mastrobattista E, Storm G, Berezikov E, Cuppen E, Woodle M, Schaapveld RQ, Prevost GP, Griffioen AW, Van Noort PI, Schiffelers RM. Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. Oncotarget 2014;5:6687-700. [PMID: 25149532 DOI: 10.18632/oncotarget.2235] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 10.6] [Reference Citation Analysis]
74 Murakami M, Zhao S, Zhao Y, Chowdhury NF, Yu W, Nishijima K, Takiguchi M, Tamaki N, Kuge Y. Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. Int J Oncol. 2012;41:1593-1600. [PMID: 22965141 DOI: 10.3892/ijo.2012.1624] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
75 Wu C, Bekaii-Saab T. CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. Chemother Res Pract. 2012;2012:359041. [PMID: 22792460 DOI: 10.1155/2012/359041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
76 Kim JH, Kim JE, Hong YS, Kim SY, Kim KP, Choi KE, Shin JH, Kim TW. Increased incidence of chemoport-related thrombosis in patients with colorectal cancer receiving bevacizumab: A single-institutional experience. Chin J Cancer Res 2018;30:460-7. [PMID: 30210226 DOI: 10.21147/j.issn.1000-9604.2018.04.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Qi H, Fan W. Value of ablation therapy in the treatment of lung metastases. Thorac Cancer 2018;9:199-207. [PMID: 29193688 DOI: 10.1111/1759-7714.12567] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
78 Li Z, Huang Y, Zhao R, Cui Y, Zhou Y, Wu X. Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis. Sci Rep 2018;8:510. [PMID: 29323221 DOI: 10.1038/s41598-017-19001-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012;7:e35629. [PMID: 22539986 DOI: 10.1371/journal.pone.0035629] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
80 Yokoo H, Takahashi H, Hagiwara M, Iwata H, Imai K, Saito Y, Matsuno N, Furukawa H. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report. World J Hepatol 2020; 12(12): 1349-1357 [PMID: 33442460 DOI: 10.4254/wjh.v12.i12.1349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Hsu JC, Lin JY, Lin PC, Lee YC. Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment. PLoS One 2019;14:e0225938. [PMID: 31830075 DOI: 10.1371/journal.pone.0225938] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Marusasa T, Hashiguchi T, Uchida T, Sakuyama N, Sato T, Kishine K, Futagawa S, Nagaoka I. Identification of responders/non-responders to 5-fluorouracil based on individual 50% inhibitory area under the concentration curve of 5-fluorouracil obtained with collagen gel droplet-embedded culture-drug sensitivity test in colorectal cancer. Oncol Lett 2011;2:309-13. [PMID: 22866082 DOI: 10.3892/ol.2011.251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
83 Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107:pii: dju427. [PMID: 25713148 DOI: 10.1093/jnci/dju427] [Cited by in Crossref: 221] [Cited by in F6Publishing: 237] [Article Influence: 31.6] [Reference Citation Analysis]
84 Ren T, Wang S, Shen Z, Xu C, Zhang Y, Hui F, Qi X, Zhao Q. Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. Drug Saf 2021;44:29-40. [PMID: 33180265 DOI: 10.1007/s40264-020-00997-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Zhang C, Aldrees M, Arif M, Li X, Mardinoglu A, Aziz MA. Elucidating the Reprograming of Colorectal Cancer Metabolism Using Genome-Scale Metabolic Modeling. Front Oncol 2019;9:681. [PMID: 31417867 DOI: 10.3389/fonc.2019.00681] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
86 Qu CY, Zheng Y, Zhou M, Zhang Y, Shen F, Cao J, Xu LM. Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. World J Gastroenterol 2015; 21(16): 5072-5080 [PMID: 25945023 DOI: 10.3748/wjg.v21.i16.5072] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
87 Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, Yu SY, Ba Y, Liang J, Wang D, Qin SK, Wang JJ, He J, Qi C, Xu RH. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 2011;30:682-9. [PMID: 21959045 DOI: 10.5732/cjc.011.10188] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 7.7] [Reference Citation Analysis]
88 Aparicio J, Esposito F, Serrano S, Falco E, Escudero P, Ruiz-Casado A, Manzano H, Fernandez-Montes A. Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. J Clin Med 2020;9:E3889. [PMID: 33265959 DOI: 10.3390/jcm9123889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Liu F, Zhao J, Xie J, Xie L, Zhu J, Cai S, Zheng H, Xu Y. Prognostic risk factors in patients with bone metastasis from colorectal cancer. Tumour Biol 2016. [PMID: 27734341 DOI: 10.1007/s13277-016-5465-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
90 Nakayama G, Mitsuma A, Sunagawa Y, Ishigure K, Yokoyama H, Matsui T, Nakayama H, Nakata K, Ishiyama A, Asada T, Umeda S, Ezaka K, Hattori N, Takami H, Kobayashi D, Tanaka C, Kanda M, Yamada S, Koike M, Fujiwara M, Fujii T, Murotani K, Ando Y, Kodera Y. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study). Oncologist 2018;23:919-27. [PMID: 30049885 DOI: 10.1634/theoncologist.2017-0640] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
91 Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387:2008-2016. [PMID: 26969090 DOI: 10.1016/s0140-6736(16)00559-6] [Cited by in Crossref: 342] [Cited by in F6Publishing: 156] [Article Influence: 57.0] [Reference Citation Analysis]
92 Altunel E, Roghani RS, Chen KY, Kim SY, McCall S, Ware KE, Shen X, Somarelli JA, Hsu DS. Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer. BMC Cancer 2020;20:592. [PMID: 32580713 DOI: 10.1186/s12885-020-07090-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Schoffelen R, Boerman OC, Goldenberg DM, Sharkey RM, van Herpen CM, Franssen GM, McBride WJ, Chang CH, Rossi EA, van der Graaf WT, Oyen WJ. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer 2013;109:934-42. [PMID: 23860529 DOI: 10.1038/bjc.2013.376] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
94 Rapisarda A, Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 2012;9:378-90. [PMID: 22525710 DOI: 10.1038/nrclinonc.2012.64] [Cited by in Crossref: 115] [Cited by in F6Publishing: 102] [Article Influence: 11.5] [Reference Citation Analysis]
95 Eadens MJ, Grothey A. Curable metastatic colorectal cancer. Curr Oncol Rep. 2011;13:168-176. [PMID: 21298372 DOI: 10.1007/s11912-011-0157-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
96 Agcaoglu O, Aliyev S, Karabulut K, El-Gazzaz G, Aucejo F, Pelley R, Siperstein AE, Berber E. Complementary use of resection and radiofrequency ablation for the treatment of colorectal liver metastases: an analysis of 395 patients. World J Surg 2013;37:1333-9. [PMID: 23460452 DOI: 10.1007/s00268-013-1981-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
97 Rosa B, de Jesus JP, de Mello EL, Cesar D, Correia MM. Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. Ecancermedicalscience 2015;9:582. [PMID: 26557880 DOI: 10.3332/ecancer.2015.582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
98 Chiorean EG, Nandakumar G, Fadelu T, Temin S, Alarcon-Rozas AE, Bejarano S, Croitoru AE, Grover S, Lohar PV, Odhiambo A, Park SH, Garcia ER, Teh C, Rose A, Zaki B, Chamberlin MD. Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline.JCO Glob Oncol. 2020;6:414-438. [PMID: 32150483 DOI: 10.1200/JGO.19.00367] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 19.0] [Reference Citation Analysis]
99 Reinacher-Schick A. [Systemic treatment of advanced colorectal cancer]. Pathologe 2008;29 Suppl 2:191-5. [PMID: 18791719 DOI: 10.1007/s00292-008-1071-6] [Reference Citation Analysis]
100 Cheng YD, Yang H, Chen GQ, Zhang ZC. Molecularly targeted drugs for metastatic colorectal cancer. Drug Des Devel Ther 2013;7:1315-22. [PMID: 24204124 DOI: 10.2147/DDDT.S52485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 20] [Article Influence: 0.4] [Reference Citation Analysis]
101 Tharin Z, Blanc J, Alaoui IC, Bertaut A, Ghiringhelli F. Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancer. J Gastrointest Oncol 2021;12:1509-17. [PMID: 34532106 DOI: 10.21037/jgo-20-593] [Reference Citation Analysis]
102 Ronnekleiv-Kelly SM, Kennedy GD. Management of stage IV rectal cancer: Palliative options. World J Gastroenterol 2011; 17(7): 835-847 [PMID: 21412493 DOI: 10.3748/wjg.v17.i7.835] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
103 Fiala O, Ostasov P, Sorejs O, Liska V, Buchler T, Poprach A, Finek J. Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients. Cancers (Basel) 2019;11:E1856. [PMID: 31769417 DOI: 10.3390/cancers11121856] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
104 Janku F, Wheler JJ, Hong DS, Kurzrock R. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Target Oncol 2013;8:183-8. [PMID: 23400451 DOI: 10.1007/s11523-013-0266-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
105 El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther 2015;16:1726-37. [PMID: 26553611 DOI: 10.1080/15384047.2015.1113356] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 7.7] [Reference Citation Analysis]
106 Okita NT, Esaki T, Baba E, Sakai D, Tokunaga S, Takiuchi H, Mizunuma N, Nagashima K, Kato K. A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer. Invest New Drugs 2012;30:2026-31. [PMID: 22160802 DOI: 10.1007/s10637-011-9779-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
107 Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep. 2012;14:277-284. [PMID: 22532266 DOI: 10.1007/s11912-012-0238-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
108 Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015;16:937-48. [PMID: 26184520 DOI: 10.1016/S1470-2045(15)00138-2] [Cited by in Crossref: 209] [Cited by in F6Publishing: 117] [Article Influence: 29.9] [Reference Citation Analysis]
109 Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol. 2012;9:561-570. [PMID: 22910681 DOI: 10.1038/nrclinonc.2012.137] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 7.3] [Reference Citation Analysis]
110 Ahn DH, Goldberg RM. Colorectal clinical trials: what is on the horizon? Future Oncol 2016;12:525-31. [PMID: 26777152 DOI: 10.2217/fon.15.327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
111 Kiss I, Mlčochová J, Součková K, Fabian P, Poprach A, Halamkova J, Svoboda M, Vyzula R, Slaby O. MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX. Oncol Lett 2017;14:743-50. [PMID: 28693229 DOI: 10.3892/ol.2017.6255] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
112 Bailey CH, Jameson G, Sima C, Fleck S, White E, Von Hoff DD, Weiss GJ. Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J Cancer 2012;3:7-13. [PMID: 22211140 DOI: 10.7150/jca.3.7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
113 Ryanne Wu R, Lindenberg PA, Slack R, Noone AM, Marshall JL, He AR. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer. 2009;40:101-108. [PMID: 19921473 DOI: 10.1007/s12029-009-9104-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
114 Chen X, Qiu H, Chen Y, Wang M, Zhu P, Pan S, Deng Y, Yang L, Chen Z. A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:690515. [PMID: 34868908 DOI: 10.3389/fonc.2021.690515] [Reference Citation Analysis]
115 Mahapatro M, Erkert L, Becker C. Cytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut. Cells 2021;10:111. [PMID: 33435303 DOI: 10.3390/cells10010111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
116 Steeg PS. Targeting metastasis. Nat Rev Cancer 2016;16:201-18. [PMID: 27009393 DOI: 10.1038/nrc.2016.25] [Cited by in Crossref: 671] [Cited by in F6Publishing: 637] [Article Influence: 111.8] [Reference Citation Analysis]
117 Yamaguchi K, Taniguchi H, Komori A, Narita Y, Nitta S, Nomura M, Kadowaki S, Takahari D, Ura T, Andoh M, Muro K, Mori K, Igarashi Y. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. BMC Cancer 2015;15:601. [PMID: 26311588 DOI: 10.1186/s12885-015-1606-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
118 Kawazoe H, Sumikawa S, Nakauchi K, Yakushijin Y, Yamamoto Y, Watanabe Y, Tanaka A, Araki H. Preventive effect of pre-warming, hot compress, and pH adjustment in oxaliplatin-induced venous pain. Int J Clin Pharm 2017;39:1291-7. [PMID: 29027645 DOI: 10.1007/s11096-017-0536-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
119 Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br J Cancer. 2009;101:12-18. [PMID: 19491895 DOI: 10.1038/sj.bjc.6605114] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
120 Geva R, Vecchione L, Tejpar S, Piessevaux H, Van Cutsem E, Prenen H. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. Onco Targets Ther. 2013;6:53-58. [PMID: 23378775 DOI: 10.2147/ott.s41383] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
121 Nakayama G, Ishigure K, Yokoyama H, Uehara K, Kojima H, Ishiyama A, Hayashi N, Takano N, Hattori N, Kobayashi D, Tanaka C, Hayashi M, Kanda M, Yamada S, Sugimoto H, Koike M, Fujiwara M, Fujii T, Murotani K, Ando Y, Kodera Y. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902). BMC Cancer 2017;17:243. [PMID: 28376737 DOI: 10.1186/s12885-017-3245-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
122 Neerincx M, Poel D, Sie DLS, van Grieken NCT, Shankaraiah RC, van der Wolf-de Lijster FSW, van Waesberghe JTM, Burggraaf JD, Eijk PP, Verhoef C, Ylstra B, Meijer GA, van de Wiel MA, Buffart TE, Verheul HMW. Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer. PLoS One 2018;13:e0201809. [PMID: 30075027 DOI: 10.1371/journal.pone.0201809] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
123 Park DY, Choi C, Shin E, Lee JH, Kwon CH, Jo HJ, Kim HR, Kim HS, Oh N, Lee JS, Park OK, Park E, Park J, Shin JY, Kim JI, Seo JS, Park HD, Park J. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer. Oncotarget 2016;7:8399-412. [PMID: 26716414 DOI: 10.18632/oncotarget.6724] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
124 Ogata Y, Shimokawa M, Tanaka T, Emi Y, Oki E, Saeki H, Sadanaga N, Kusumoto T, Touyama T, Kimura M, Baba H, Akagi Y, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). Int J Clin Oncol 2016;21:335-43. [PMID: 26338269 DOI: 10.1007/s10147-015-0895-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
125 Chaudhury P, Hassanain M, Bouganim N, Salman A, Kavan P, Metrakos P. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. HPB (Oxford) 2010;12:37-42. [PMID: 20495643 DOI: 10.1111/j.1477-2574.2009.00119.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
126 Moriwaki T, Gosho M, Sugaya A, Yamada T, Yamamoto Y, Hyodo I. Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis. Cancer Res Treat 2021;53:703-13. [PMID: 33285056 DOI: 10.4143/crt.2020.805] [Reference Citation Analysis]
127 Lee SY, Oh SC. Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. Biomed Res Int. 2016;2016:7590245. [PMID: 27127793 DOI: 10.1155/2016/7590245] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
128 Takenami T, Tsujinaka S, Takahashi J, Tamaki S, Maemoto R, Fukuda R, Ishikawa H, Kakizawa N, Hasegawa F, Kikugawa R, Miyakura Y, Suzuki K, Tanaka A, Rikiyama T. Efficacy of Neoadjuvant Chemotherapy with Capecitabine plus Oxaliplatin in the Treatment of Locally Advanced Sigmoid Colon Cancer Invading the Urinary Bladder: A Report of Three Cases. Case Rep Surg 2019;2019:8129358. [PMID: 31049241 DOI: 10.1155/2019/8129358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
129 Takao M, Yamazaki K, Boku N, Ikehara H, Hamauchi S, Tsushima T, Taniguchi H, Todaka A, Machida N, Fukutomi A, Onozawa Y, Yasui H. Endoscopic evaluation of primary tumor response in patients with metastatic colorectal cancer treated by systemic chemotherapy. Int J Clin Oncol 2013;18:864-8. [PMID: 22865286 DOI: 10.1007/s10147-012-0452-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
130 Costi R, Leonardi F, Zanoni D, Violi V, Roncoroni L. Palliative care and end-stage colorectal cancer management: The surgeon meets the oncologist. World J Gastroenterol 2014; 20(24): 7602-7621 [PMID: 24976699 DOI: 10.3748/wjg.v20.i24.7602] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
131 Lu L, Dercle L, Zhao B, Schwartz LH. Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging. Nat Commun 2021;12:6654. [PMID: 34789774 DOI: 10.1038/s41467-021-26990-6] [Reference Citation Analysis]
132 Loupakis F, Hurwitz HI, Saltz L, Arnold D, Grothey A, Nguyen QL, Osborne S, Talbot J, Srock S, Lenz HJ. Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. Br J Cancer 2018;119:1451-5. [PMID: 30487637 DOI: 10.1038/s41416-018-0304-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
133 Tezuka T, Hamada C, Ishida H, Ooshiro M, Matsuoka H, Kawasaki S, Mishima H, Maeda K, Sakamoto J, Koda K. Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study. Invest New Drugs. 2013;31:1321-1329. [PMID: 23817973 DOI: 10.1007/s10637-013-9982-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
134 Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy.J Gastrointest Oncol. 2016;7:45-57. [PMID: 26941983 DOI: 10.3978/j.issn.2078-6891.2015.111] [Cited by in F6Publishing: 35] [Reference Citation Analysis]
135 Bangi E, Ang C, Smibert P, Uzilov AV, Teague AG, Antipin Y, Chen R, Hecht C, Gruszczynski N, Yon WJ, Malyshev D, Laspina D, Selkridge I, Rainey H, Moe AS, Lau CY, Taik P, Wilck E, Bhardwaj A, Sung M, Kim S, Yum K, Sebra R, Donovan M, Misiukiewicz K, Schadt EE, Posner MR, Cagan RL. A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer. Sci Adv. 2019;5:eaav6528. [PMID: 31131321 DOI: 10.1126/sciadv.aav6528] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
136 Kitahara M, Hazama S, Tsunedomi R, Takenouchi H, Kanekiyo S, Inoue Y, Nakajima M, Tomochika S, Tokuhisa Y, Iida M, Sakamoto K, Suzuki N, Takeda S, Ueno T, Yamamoto S, Yoshino S, Nagano H. Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer. Cancer Sci 2016;107:1825-9. [PMID: 27663862 DOI: 10.1111/cas.13085] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
137 Franchi M, Barni S, Tagliabue G, Ricci P, Mazzucco W, Tumino R, Caputo A, Corrao G; GRETA working group. Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA. Oncologist 2019;24:358-65. [PMID: 30097524 DOI: 10.1634/theoncologist.2017-0314] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
138 Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 2015;121:1025-31. [PMID: 25417775 DOI: 10.1002/cncr.29169] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
139 Baird R, Biondo A, Chhaya V, McLachlan J, Karpathakis A, Rahman S, Barbachano Y, Cunningham D, Chau I. Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. Br J Cancer 2011;104:43-50. [PMID: 21063416 DOI: 10.1038/sj.bjc.6605995] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
140 Haslem DS, Ji HP, Ford JM, Nadauld LD. Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine. JCO Precis Oncol 2017;1:PO. [PMID: 32913966 DOI: 10.1200/PO.16.00055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
141 Strickler JH, Hurwitz HI. Palliative treatment of metastatic colorectal cancer: what is the optimal approach? Curr Oncol Rep 2014;16:363. [PMID: 24293074 DOI: 10.1007/s11912-013-0363-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
142 Iwai T, Harada Y, Saeki H, Oki E, Maehara Y, Yonemitsu Y. Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11bhigh/Gr1high myeloid cells. Oncotarget 2018;9:17620-30. [PMID: 29707135 DOI: 10.18632/oncotarget.24811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
143 Birkeland AC, Brenner JC. Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: The Rationale for Combination Therapies. Med Res Arch 2015;3. [PMID: 26913293 DOI: 10.18103/mra.v0i3.77] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
144 Kim JW, Lee KW, Kim KP, Lee JH, Hong YS, Kim JE, Kim SY, Park SR, Nam BH, Cho SH, Chung IJ, Park YS, Oh HS, Lee MA, Kang HJ, Park YI, Song EK, Han HS, Lee KT, Shin DB, Kang JH, Zang DY, Kim JH, Kim TW. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. Oncologist 2017;22:293-303. [PMID: 28209749 DOI: 10.1634/theoncologist.2016-0166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
145 Yang PS, Wang JJ, Wang YH, Jan WC, Cheng SP, Hsu YC. 1,6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl] diamantane potentiates in vitro and in vivo antitumor effects of irinotecan on human colorectal cancer cells. Oncol Lett 2016;11:3551-7. [PMID: 27123150 DOI: 10.3892/ol.2016.4430] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
146 Qi WX, Shen Z, Tang LN, Yao Y. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol. 2014;70:893-906. [PMID: 24858820 DOI: 10.1007/s00228-014-1687-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
147 Yasuno M, Uetake H, Ishiguro M, Mizunuma N, Komori T, Miyata G, Shiomi A, Kagimura T, Sugihara K. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival. Int J Clin Oncol 2019;24:516-25. [PMID: 30612267 DOI: 10.1007/s10147-018-01393-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
148 Lee JJ, Chu E. Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018;17:258-273. [PMID: 30072278 DOI: 10.1016/j.clcc.2018.06.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
149 Nakajima J. Pulmonary metastasis: rationale for local treatments and techniques. Gen Thorac Cardiovasc Surg 2010;58:445-51. [PMID: 20859722 DOI: 10.1007/s11748-010-0609-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
150 Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012;30:4566-4572. [PMID: 23150701 DOI: 10.1200/jco.2012.45.2854] [Cited by in Crossref: 138] [Cited by in F6Publishing: 58] [Article Influence: 13.8] [Reference Citation Analysis]
151 Bouganim N, Mamo A, Wasserman DW, Batist G, Metrakos P, Chaudhury P, Hassanain M, Kavan P. Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009. Curr Oncol 2013;20:247-51. [PMID: 24155628 DOI: 10.3747/co.20.1370] [Reference Citation Analysis]
152 Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer. 2009;100:1704-1719. [PMID: 19436303 DOI: 10.1038/sj.bjc.6605061] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 5.8] [Reference Citation Analysis]
153 Bazarbashi S, Aljubran A, Alzahrani A, Mohieldin A, Soudy H, Shoukri M. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer. Cancer Med 2015;4:1505-13. [PMID: 26207614 DOI: 10.1002/cam4.497] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
154 Komori H, Beppu T, Baba Y, Horino K, Imsung C, Masuda T, Hayashi H, Okabe H, Ootao R, Watanabe M, Takamori H, Iyama K, Baba H. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients. Int J Clin Oncol 2010;15:263-70. [DOI: 10.1007/s10147-010-0046-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
155 Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, Yamada Y, Watanabe D, Ishihara T, Suzuki A, Yoshida K. Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study. Oncologist 2020;25:e469-76. [PMID: 32162797 DOI: 10.1634/theoncologist.2019-0541] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
156 Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer 2012;43:562-9. [PMID: 22294255 DOI: 10.1007/s12029-012-9368-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
157 Palethorpe HM, Tomita Y, Smith E, Pei JV, Townsend AR, Price TJ, Young JP, Yool AJ, Hardingham JE. The Aquaporin 1 Inhibitor Bacopaside II Reduces Endothelial Cell Migration and Tubulogenesis and Induces Apoptosis. Int J Mol Sci 2018;19:E653. [PMID: 29495367 DOI: 10.3390/ijms19030653] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
158 Rossi L, Zullo A, Zoratto F, Papa A, Strudel M, Colonna M, Tomao S. Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases. Oncol Rev 2012;6:e6. [PMID: 25992208 DOI: 10.4081/oncol.2012.e6] [Reference Citation Analysis]
159 Mack JW, Cronin A, Taback N, Huskamp HA, Keating NL, Malin JL, Earle CC, Weeks JC. End-of-life care discussions among patients with advanced cancer: a cohort study. Ann Intern Med 2012;156:204-10. [PMID: 22312140 DOI: 10.7326/0003-4819-156-3-201202070-00008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
160 Doi A, Takeda H, Umemoto K, Oumi R, Wada S, Hamaguchi S, Mimura H, Arai H, Horie Y, Mizukami T, Izawa N, Ogura T, Nakajima TE, Sunakawa Y. Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report. World J Gastrointest Oncol 2020; 12(11): 1364-1371 [PMID: 33250967 DOI: 10.4251/wjgo.v12.i11.1364] [Cited by in CrossRef: 2] [Article Influence: 1.0] [Reference Citation Analysis]
161 Feng Y, Mo S, Dai W, Li Q, Cai G, Cai S. Increasing age-related survival gap among patients with colorectal cancer: a population-based retrospective study. Int J Clin Oncol 2020;25:100-9. [PMID: 31531787 DOI: 10.1007/s10147-019-01538-3] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
162 Wang Y, Yao X, Ge J, Hu F, Zhao Y. Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis. ScientificWorldJournal. 2014;2014:102736. [PMID: 25143961 DOI: 10.1155/2014/102736] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
163 Burzykowski T, Coart E, Saad ED, Shi Q, Sommeijer DW, Bokemeyer C, Díaz-Rubio E, Douillard JY, Falcone A, Fuchs CS, Goldberg RM, Hecht JR, Hoff PM, Hurwitz H, Kabbinavar FF, Koopman M, Maughan TS, Punt CJA, Saltz L, Schmoll HJ, Seymour MT, Tebbutt NC, Tournigand C, Van Cutsem E, de Gramont A, Zalcberg JR, Buyse M; Aide et Recherche en Cancerologie Digestive Group. Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Netw Open 2019;2:e1911750. [PMID: 31539075 DOI: 10.1001/jamanetworkopen.2019.11750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
164 Leite D, Kater FR. Conversion treatment of hepatic metastases of colon adenocarcinoma by bevacizumab and FOLFOX. Anticancer Drugs 2011;22 Suppl 2:S1-7. [PMID: 21768791 DOI: 10.1097/01.cad.0000398726.60837.27] [Reference Citation Analysis]
165 Vera R, Gómez ML, Ayuso JR, Figueras J, García-Alfonso P, Martínez V, Lacasta A, Ruiz-Casado A, Safont MJ, Aparicio J, Campos JM, Cámara JC, Martín-Richard M, Montagut C, Pericay C, Vieitez JM, Falcó E, Jorge M, Marín M, Salgado M, Viúdez A. Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study. Cancers (Basel) 2020;12:E2259. [PMID: 32806731 DOI: 10.3390/cancers12082259] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
166 Moscetti L, Nelli F, Fabbri MA, Sperduti I, Alesini D, Cortesi E, Gemma D, Gamucci T, Grande R, Pavese I. Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study. Invest New Drugs. 2013;31:1035-1043. [PMID: 23417697 DOI: 10.1007/s10637-013-9936-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
167 Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O'Reilly S, Chu L, Azar CA, Lopa S, Wolmark N. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11-16. [PMID: 20940184 DOI: 10.1200/jco.2010.30.0855] [Cited by in Crossref: 415] [Cited by in F6Publishing: 193] [Article Influence: 34.6] [Reference Citation Analysis]
168 Pelz JO, Chua TC, Esquivel J, Stojadinovic A, Doerfer J, Morris DL, Maeder U, Germer CT, Kerscher AG. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer. 2010;10:689. [PMID: 21176206 DOI: 10.1186/1471-2407-10-689] [Cited by in Crossref: 78] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
169 Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol. 2012;5:63. [PMID: 23057939 DOI: 10.1186/1756-8722-5-63] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
170 Nakagawa Y, Yoshimoto T, Nakagawa S, Sugitani Y, Yamamoto H, Asakawa T. Impact of Tumor Assessment Frequency on Statistical Power in Randomized Cancer Clinical Trials Evaluating Progression-Free Survival. Ther Innov Regul Sci 2021. [PMID: 34319577 DOI: 10.1007/s43441-021-00328-2] [Reference Citation Analysis]
171 Nakayama N, Sato A, Tanaka S, Shimada K, Konishi K, Sasaki E, Hibi K, Ichikawa H, Kikuchi Y, Sakuyama T, Sekikawa T, Hayashi K, Nishina H; Tokyo Cooperative Oncology Group, Tokyo, Japan. A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study. Invest New Drugs 2015;33:954-62. [PMID: 25937430 DOI: 10.1007/s10637-015-0239-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
172 Cho T, Shiozawa E, Urushibara F, Arai N, Funaki T, Takehara Y, Tazawa S, Misawa M, Homma M, Norose T, Omatsu M, Miyachi H, Yamochi T, Kunimura T, Tate G, Ishida F, Kudo SE, Takimoto M. The role of microvessel density, lymph node metastasis, and tumor size as prognostic factors of distant metastasis in colorectal cancer. Oncol Lett. 2017;13:4327-4333. [PMID: 28599434 DOI: 10.3892/ol.2017.5959] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
173 Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L. Role of oxaliplatin in the treatment of colorectal cancer. Ther Clin Risk Manag 2009;5:229-38. [PMID: 19436599 DOI: 10.2147/tcrm.s3583] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
174 Hochster HS, Grothey A, Hart L, Rowland K, Ansari R, Alberts S, Chowhan N, Ramanathan RK, Keaton M, Hainsworth JD, Childs BH. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol 2014;25:1172-8. [PMID: 24608198 DOI: 10.1093/annonc/mdu107] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
175 García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist 2017;22:375-e30. [PMID: 28275117 DOI: 10.1634/theoncologist.2016-0133] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
176 Li L, Ma BB. Colorectal cancer in Chinese patients: current and emerging treatment options. Onco Targets Ther. 2014;7:1817-1828. [PMID: 25336973 DOI: 10.2147/OTT.S48409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 22] [Article Influence: 0.4] [Reference Citation Analysis]
177 Arai H, Battaglin F, Wang J, Lo JH, Soni S, Zhang W, Lenz HJ. Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev 2019;81:101912. [PMID: 31715423 DOI: 10.1016/j.ctrv.2019.101912] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
178 Weldon Gilcrease G, Stenehjem DD, Wade ML, Weis J, McGregor K, Whisenant J, Boucher KM, Thorne K, Orgain N, Garrido-Laguna I, Sharma S. Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. Invest New Drugs. 2019;37:482-489. [PMID: 30302599 DOI: 10.1007/s10637-018-0645-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
179 Miyo M, Kato T, Yoshino T, Yamanaka T, Bando H, Satake H, Yamazaki K, Taniguchi H, Oki E, Kotaka M, Oba K, Miyata Y, Muro K, Komatsu Y, Baba H, Tsuji A. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. BMC Cancer 2020;20:687. [PMID: 32703200 DOI: 10.1186/s12885-020-07186-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A. Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol. 2015;6:185-200. [PMID: 25830038 DOI: 10.3978/j.issn.2078-6891.2014.112] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
181 Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Translating genomic profiling to gastrointestinal cancer treatment. Future Oncol 2017;13:919-34. [PMID: 28067073 DOI: 10.2217/fon-2016-0422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
182 Dattatreya S. Metastatic colorectal cancer-prolonging overall survival with targeted therapies. South Asian J Cancer 2013;2:179-85. [PMID: 24455615 DOI: 10.4103/2278-330X.114152] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
183 Lu M, Zessin AS, Glover W, Hsu DS. Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis. PLoS One 2017;12:e0169439. [PMID: 28060954 DOI: 10.1371/journal.pone.0169439] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
184 Li J, Xu R, Xu J, Denda T, Ikejiri K, Shen L, Toh Y, Shimada K, Kato T, Sakai K, Yamamoto M, Mishima H, Wang J, Baba H. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. Cancer Sci 2017;108:2045-51. [PMID: 28763145 DOI: 10.1111/cas.13335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
185 Boisen MK, Dehlendorff C, Linnemann D, Nielsen BS, Larsen JS, Osterlind K, Nielsen SE, Tarpgaard LS, Qvortrup C, Pfeiffer P. Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab. PLoS One. 2014;9:e109430. [PMID: 25329796 DOI: 10.1371/journal.pone.0109430] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
186 Mitchell AP, Kinlaw AC, Peacock-Hinton S, Dusetzina SB, Sanoff HK, Lund JL. Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. Oncologist 2020;25:46-54. [PMID: 31611329 DOI: 10.1634/theoncologist.2019-0338] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
187 Yoshihiro T, Kusaba H, Makiyama A, Kobayashi K, Uenomachi M, Ito M, Doi Y, Mitsugi K, Aikawa T, Takayoshi K, Esaki T, Shimokawa H, Tsuchihashi K, Ariyama H, Akashi K, Baba E. Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. Int J Clin Oncol. 2019;24:508-515. [PMID: 30604155 DOI: 10.1007/s10147-018-01391-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
188 Fiala O, Buchler T, Mohelnikova-Duchonova B, Melichar B, Matejka VM, Holubec L, Kulhankova J, Bortlicek Z, Bartouskova M, Liska V, Topolcan O, Sedivcova M, Finek J. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol 2016;37:6823-30. [PMID: 26662311 DOI: 10.1007/s13277-015-4523-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
189 Wakai T, Shirai Y, Sakata J, Kameyama H, Nogami H, Iiai T, Ajioka Y, Hatakeyama K. Histologic evaluation of intrahepatic micrometastases in patients treated with or without neoadjuvant chemotherapy for colorectal carcinoma liver metastasis. Int J Clin Exp Pathol. 2012;5:308-314. [PMID: 22670174 DOI: 10.4132/koreanjpathol.2012.46.4.399] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
190 Nakashima-Nakasuga C, Hazama S, Suzuki N, Nakagami Y, Xu M, Yoshida S, Tomochika S, Fujiwara N, Matsukuma S, Matsui H, Tokumitsu Y, Kanekiyo S, Shindo Y, Maeda N, Tsunedomi R, Iida M, Takeda S, Yoshino S, Ueno T, Hamamoto Y, Ogihara H, Hoshii Y, Nagano H. Serum LOX-1 is a novel prognostic biomarker of colorectal cancer. Int J Clin Oncol 2020;25:1308-17. [PMID: 32277394 DOI: 10.1007/s10147-020-01673-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
191 Chen D, Zhang X, Gao G, Shen L, Xie J, Qian X, Wang H. Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis. World J Surg Oncol 2018;16:200. [PMID: 30296945 DOI: 10.1186/s12957-018-1502-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
192 da Silva WC, de Araujo VE, Lima EMEA, Dos Santos JBR, Silva MRRD, Almeida PHRF, de Assis Acurcio F, Godman B, Kurdi A, Cherchiglia ML, Andrade EIG. Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. BioDrugs 2018;32:585-606. [PMID: 30499082 DOI: 10.1007/s40259-018-0322-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
193 Hofheinz R, Petersen V, Kindler M, Schulze M, Seraphin J, Hoeffkes HG, Valdix AR, Schroeder J, Herrenberger J, Stein A. Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results. BMC Cancer. 2014;14:761. [PMID: 25311943 DOI: 10.1186/1471-2407-14-761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
194 Park EJ, Baek JH, Choi GS, Park WC, Yu CS, Kang SB, Min BS, Kim JH, Kim HR, Lee BH, Oh JH, Jeong SY, Jung M, Ahn JB, Baik SH. The Role of Primary Tumor Resection in Colorectal Cancer Patients with Asymptomatic, Synchronous, Unresectable Metastasis: A Multicenter Randomized Controlled Trial. Cancers (Basel) 2020;12:E2306. [PMID: 32824392 DOI: 10.3390/cancers12082306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
195 Tejpar S, Prenen H, Mazzone M. Overcoming resistance to antiangiogenic therapies. Oncologist. 2012;17:1039-1050. [PMID: 22773560 DOI: 10.1634/theoncologist.2012-0068] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
196 Arimoto A, Uehara K, Tsuzuki T, Aiba T, Ebata T, Nagino M. Role of bevacizumab in neoadjuvant chemotherapy and its influence on microvessel density in rectal cancer. Int J Clin Oncol 2015;20:935-42. [PMID: 25788218 DOI: 10.1007/s10147-015-0818-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
197 Liu W, Liu L, Wang R, Gong G, Ding X, Yang B, Bao Y, Wang Z, Zhang B, Zhao D, Wu F, Ding Y. Bevacizumab Combined With Oxaliplatin/Capecitabine in Patient With Refractory and Recurrent Mucinous Adenocarcinoma of the Appendix: A Case Report. Front Oncol 2019;9:55. [PMID: 30792968 DOI: 10.3389/fonc.2019.00055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
198 Maneikyte J, Bausys A, Leber B, Horvath A, Feldbacher N, Hoefler G, Strupas K, Stiegler P, Schemmer P. Dietary glycine decreases both tumor volume and vascularization in a combined colorectal liver metastasis and chemotherapy model. Int J Biol Sci 2019;15:1582-90. [PMID: 31360101 DOI: 10.7150/ijbs.35513] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
199 Totzeck M, Mincu RI, Rassaf T. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients. J Am Heart Assoc 2017;6:e006278. [PMID: 28862931 DOI: 10.1161/JAHA.117.006278] [Cited by in Crossref: 50] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
200 Ismaili N. Treatment of colorectal liver metastases. World J Surg Oncol. 2011;9:154. [PMID: 22115124 DOI: 10.1186/1477-7819-9-154] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
201 Pili R, Carducci M, Brown P, Hurwitz H. An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. Invest New Drugs 2014;32:1258-68. [PMID: 25152243 DOI: 10.1007/s10637-014-0147-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
202 Liu C, Alwarappan S, Badr HA, Zhang R, Liu H, Zhu JJ, Li CZ. Live cell integrated surface plasmon resonance biosensing approach to mimic the regulation of angiogenic switch upon anti-cancer drug exposure. Anal Chem 2014;86:7305-10. [PMID: 25005895 DOI: 10.1021/ac402659j] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
203 Wang HW, Yang SH, Huang GD, Lin JK, Chen WS, Jiang JK, Lan YT, Lin CC, Hwang WL, Tzeng CH, Li AF, Yen CC, Teng HW. Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism. J Cancer Res Clin Oncol 2014;140:561-71. [PMID: 24493623 DOI: 10.1007/s00432-014-1596-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
204 Legué LM, van Erning FN, Bernards N, Lemmens VEPP, de Hingh IHJT, Creemers GJ. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study. Target Oncol 2019;14:699-705. [PMID: 31625001 DOI: 10.1007/s11523-019-00681-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
205 Kuo YH, Lin CH, Shau WY, Chen TJ, Yang SH, Huang SM, Hsu C, Lu YS, Cheng AL. Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. BMC Cancer 2012;12:620. [PMID: 23268621 DOI: 10.1186/1471-2407-12-620] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
206 Hopirtean C, Nagy V. Optimizing the use of anti VEGF targeted therapies in patients with metastatic colorectal cancer: review of literature. Clujul Med 2018;91:12-7. [PMID: 29440946 DOI: 10.15386/cjmed-881] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
207 Yamakawa M, Doh SJ, Santosa SM, Montana M, Qin EC, Kong H, Han KY, Yu C, Rosenblatt MI, Kazlauskas A, Chang JH, Azar DT. Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review. Med Res Rev 2018;38:1769-98. [PMID: 29528507 DOI: 10.1002/med.21496] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
208 Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 2013;108:1052-1060. [PMID: 23422754 DOI: 10.1038/bjc.2013.69] [Cited by in Crossref: 115] [Cited by in F6Publishing: 100] [Article Influence: 12.8] [Reference Citation Analysis]
209 Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer 2010;10:567. [PMID: 20958992 DOI: 10.1186/1471-2407-10-567] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
210 Neerincx M, Sie DL, van de Wiel MA, van Grieken NC, Burggraaf JD, Dekker H, Eijk PP, Ylstra B, Verhoef C, Meijer GA, Buffart TE, Verheul HM. MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing. Oncogenesis 2015;4:e170. [PMID: 26436952 DOI: 10.1038/oncsis.2015.29] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
211 Meropol NJ, Feng Y, Grem JL, Mulcahy MF, Catalano PJ, Kauh JS, Hall MJ, Saltzman JN, George TJ Jr, Zangmeister J, Chiorean EG, Cheema PS, O'Dwyer PJ, Benson AB 3rd. Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer 2018;124:688-97. [PMID: 29211295 DOI: 10.1002/cncr.30967] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
212 Li L, Ma BB. Colorectal cancer in Chinese patients: current and emerging treatment options. Onco Targets Ther. 2014;7:1817-1828. [PMID: 25336973 DOI: 10.2147/OTT.S48409ott-7-1817] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
213 Lannagan TR, Jackstadt R, Leedham SJ, Sansom OJ. Advances in colon cancer research: in vitro and animal models. Curr Opin Genet Dev 2021;66:50-6. [PMID: 33422950 DOI: 10.1016/j.gde.2020.12.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
214 Stefano AD, Moretto R, Cella CA, Romano FJ, Raimondo L, Fiore G, Pietro FD, Pepe S, Placido SD, Carlomagno C. Bevacizumab maintenance in metastatic colorectal cancer: How long? World J Clin Cases 2014; 2(11): 717-723 [PMID: 25405197 DOI: 10.12998/wjcc.v2.i11.717] [Reference Citation Analysis]
215 Finkelmeier F, You SJ, Waidmann O, Wolff R, Zeuzem S, Bähr O, Trojan J. Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis. J Gastrointest Cancer 2016;47:82-8. [PMID: 26714801 DOI: 10.1007/s12029-015-9795-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
216 Mitchell D, Puckett Y, Nguyen QN. Literature Review of Current Management of Colorectal Liver Metastasis. Cureus. 2019;11:e3940. [PMID: 30937238 DOI: 10.7759/cureus.3940] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
217 Chan KK, Wong B, Siu LL, Straus SE, Chang J, Berry SR. Less than ideal: how oncologists practice with limited drug access. J Oncol Pract 2012;8:190-5. [PMID: 22942815 DOI: 10.1200/JOP.2011.000337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
218 Mori F, Ishida T, Ito A, Sato F, Masaki A, Takino H, Ri M, Kusumoto S, Komatsu H, Ueda R, Inagaki H, Iida S. Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. Blood Cancer J 2012;2:e67. [PMID: 22829969 DOI: 10.1038/bcj.2012.12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
219 Taira K, Nadatani Y, Hirano S, Maeda K, Fujiwara Y. Large Skin Ulcer and Delayed Wound Healing around a Colostomy in a Patient with Metastatic Colorectal Cancer Receiving Vascular Endothelial Growth Factor Receptor-2 Inhibitor Therapy. Case Rep Oncol 2019;12:370-5. [PMID: 31182953 DOI: 10.1159/000500412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
220 Yamane H, Matsubara M, Umemura S, Suwaki T, Kamei H, Takigawa N, Kiura K, Tanimoto M. Variant angina pectoris associated with FOLFOX4 therapy. World J Gastrointest Oncol 2011; 3(11): 165-168 [PMID: 22110843 DOI: 10.4251/wjgo.v3.i11.165] [Reference Citation Analysis]
221 Cetin B, Bilgetekin I, Cengiz M, Ozet A. Managing Synchronous Liver Metastases in Colorectal Cancer. Indian J Surg Oncol 2018;9:461-71. [PMID: 30538373 DOI: 10.1007/s13193-018-0765-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
222 Chida K, Kotani D, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okita Y, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Shimada Y. Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS). Front Oncol 2021;11:576036. [PMID: 33763345 DOI: 10.3389/fonc.2021.576036] [Reference Citation Analysis]
223 Abi-Jaoudeh N, Duffy AG, Greten TF, Kohn EC, Clark TW, Wood BJ. Personalized oncology in interventional radiology. J Vasc Interv Radiol 2013;24:1083-92; quiz 1093. [PMID: 23885909 DOI: 10.1016/j.jvir.2013.04.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
224 Janssen E, Subtil B, de la Jara Ortiz F, Verheul HMW, Tauriello DVF. Combinatorial Immunotherapies for Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E1875. [PMID: 32664619 DOI: 10.3390/cancers12071875] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
225 Hoehler T, von Wichert G, Schimanski C, Kanzler S, Moehler MH, Hinke A, Seufferlein T, Siebler J, Hochhaus A, Arnold D, Hallek M, Hofheinz R, Hacker UT. Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Br J Cancer 2013;109:1408-13. [PMID: 23963139 DOI: 10.1038/bjc.2013.409] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
226 Ayez N, van der Stok EP, de Wilt H, Radema SA, van Hillegersberg R, Roumen RM, Vreugdenhil G, Tanis PJ, Punt CJ, Dejong CH, Jansen RL, Verheul HM, de Jong KP, Hospers GA, Klaase JM, Legdeur MC, van Meerten E, Eskens FA, van der Meer N, van der Holt B, Verhoef C, Grünhagen DJ. Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial. BMC Cancer 2015;15:180. [PMID: 25884448 DOI: 10.1186/s12885-015-1199-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
227 Deshpande RP, Sharma S, Watabe K. The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. Cancers (Basel) 2020;12:E2983. [PMID: 33076303 DOI: 10.3390/cancers12102983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Patel KB, Arantes LH Jr, Tang WY, Fung S. The role of biosimilars in value-based oncology care. Cancer Manag Res 2018;10:4591-602. [PMID: 30410395 DOI: 10.2147/CMAR.S164201] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
229 Ozcelik M, Odabas H, Ercelep O, Yuksel S, Mert AG, Aydin D, Surmeli H, Isik D, Isik S, Oyman A, Oven Ustaalioglu BB, Aliustaoglu M, Gumus M. The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients. Clin Transl Oncol 2016;18:617-24. [PMID: 26459249 DOI: 10.1007/s12094-015-1408-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
230 Wang J, Zhu C. Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis. Onco Targets Ther 2016;9:4737-46. [PMID: 27536135 DOI: 10.2147/OTT.S103184] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
231 Fink DM, Steele MM, Hollingsworth MA. The lymphatic system and pancreatic cancer. Cancer Lett 2016;381:217-36. [PMID: 26742462 DOI: 10.1016/j.canlet.2015.11.048] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
232 Maisano R, Azzarello D, Del Medico P, Maisano M, Bottari M, Egitto G, Nardi M. Alkaline Phosphatase Levels as a Prognostic Factor in Metastatic Colorectal Cancer Treated with the FOLFOX 4 Regimen: A Monoinstitutional Retrospective Study. Tumori 2011;97:39-42. [DOI: 10.1177/030089161109700108] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
233 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 2012;17:1-29. [PMID: 22002491 DOI: 10.1007/s10147-011-0315-2] [Cited by in Crossref: 491] [Cited by in F6Publishing: 477] [Article Influence: 44.6] [Reference Citation Analysis]
234 Chibaudel B, Tournigand C, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:75-89. [PMID: 22423266 DOI: 10.1177/1758834011431592] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
235 Bertaut A, Touchefeu Y, Blanc J, Bouché O, François E, Conroy T, Artru P, Adenis A, Gobbo J, Borg C, Ghiringhelli F, Bennouna J. Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study. Clin Colorectal Cancer 2021:S1533-0028(21)00087-6. [PMID: 34838460 DOI: 10.1016/j.clcc.2021.09.001] [Reference Citation Analysis]
236 Glockzin G, Rochon J, Arnold D, Lang SA, Klebl F, Zeman F, Koller M, Schlitt HJ, Piso P. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer. 2013;13:67. [PMID: 23391248 DOI: 10.1186/1471-2407-13-67] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
237 Paré-Brunet L, Sebio A, Salazar J, Berenguer-Llergo A, Río E, Barnadas A, Baiget M, Páez D. Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. Pharmacogenomics J 2015;15:397-404. [PMID: 25707392 DOI: 10.1038/tpj.2015.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
238 Mack JW, Cronin A, Keating NL, Taback N, Huskamp HA, Malin JL, Earle CC, Weeks JC. Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol. 2012;30:4387-4395. [PMID: 23150700 DOI: 10.1200/jco.2012.43.6055] [Cited by in Crossref: 317] [Cited by in F6Publishing: 112] [Article Influence: 31.7] [Reference Citation Analysis]
239 Stintzing S. Management of colorectal cancer. F1000Prime Rep 2014;6:108. [PMID: 25580262 DOI: 10.12703/P6-108] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
240 Bahl A, Kapoor R, Singh PK, Bhattacharya T, Arun OS, Parsee T, Sharma SC. Locally ablative non-surgical management of colo-rectal liver metastasis. J Gastrointest Cancer 2013;44:108-10. [PMID: 22864942 DOI: 10.1007/s12029-012-9427-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
241 Ehrenberg R, Halama N. FOLFOX plus cetuximab in first-line therapy of advanced colorectal cancer. Ann Transl Med 2018;6:S96. [PMID: 30740417 DOI: 10.21037/atm.2018.11.22] [Reference Citation Analysis]
242 Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Yamaguchi N, Tanaka T, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1-34. [PMID: 28349281 DOI: 10.1007/s10147-017-1101-6] [Cited by in Crossref: 400] [Cited by in F6Publishing: 364] [Article Influence: 80.0] [Reference Citation Analysis]
243 Yoshida T, Takahashi K, Shibuya K, Muto O, Yoshida Y, Taguchi D, Shimazu K, Fukuda K, Ono F, Nomura K, Shibata H. Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture. World J Gastrointest Oncol 2021; 13(4): 295-304 [PMID: 33889280 DOI: 10.4251/wjgo.v13.i4.295] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Ilic I, Jankovic S, Ilic M. Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis. PLoS One 2016;11:e0161912. [PMID: 27579775 DOI: 10.1371/journal.pone.0161912] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
245 Jitawatanarat P, Wee W. Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. J Gastrointest Oncol 2013;4:231-8. [PMID: 23730520 DOI: 10.3978/j.issn.2078-6891.2013.008] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
246 Avallone A, Piccirillo MC, Aloj L, Nasti G, Delrio P, Izzo F, Di Gennaro E, Tatangelo F, Granata V, Cavalcanti E, Maiolino P, Bianco F, Aprea P, De Bellis M, Pecori B, Rosati G, Carlomagno C, Bertolini A, Gallo C, Romano C, Leone A, Caracò C, de Lutio di Castelguidone E, Daniele G, Catalano O, Botti G, Petrillo A, Romano GM, Iaffaioli VR, Lastoria S, Perrone F, Budillon A. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme). BMC Cancer 2016;16:69. [PMID: 26857924 DOI: 10.1186/s12885-016-2102-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
247 Shiroiwa T, Motoo Y, Tsutani K. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther 2010;14:375-84. [PMID: 21275455 DOI: 10.1007/BF03256395] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
248 Gaulin J, Kotb R, Turcotte E, Berard G, Sawan B, Schmutz G, Beauregard P. Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer. Curr Oncol 2009;16:84-6. [PMID: 19862366 DOI: 10.3747/co.v16i5.395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
249 Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) 2013;6:988-1038. [PMID: 24276379 DOI: 10.3390/ph6080988] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
250 Jayson GC, Zhou C, Backen A, Horsley L, Marti-Marti K, Shaw D, Mescallado N, Clamp A, Saunders MP, Valle JW, Mullamitha S, Braun M, Hasan J, McEntee D, Simpson K, Little RA, Watson Y, Cheung S, Roberts C, Ashcroft L, Manoharan P, Scherer SJ, Del Puerto O, Jackson A, O'Connor JPB, Parker GJM, Dive C. Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. Nat Commun 2018;9:4672. [PMID: 30405103 DOI: 10.1038/s41467-018-07174-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
251 Goldstein DA, Clark J, Tu Y, Zhang J, Fang F, Goldstein R, Stemmer SM, Rosenbaum E. A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. Oncotarget 2017;8:71548-55. [PMID: 29069727 DOI: 10.18632/oncotarget.17742] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 9.2] [Reference Citation Analysis]
252 Kim MK, Osada T, Barry WT, Yang XY, Freedman JA, Tsamis KA, Datto M, Clary BM, Clay T, Morse MA, Febbo PG, Lyerly HK, Hsu DS. Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer. Mol Cancer Ther 2012;11:1500-9. [PMID: 22351745 DOI: 10.1158/1535-7163.MCT-11-0937] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
253 Flaig TW, Kim FJ, La Rosa FG, Breaker K, Schoen J, Russ PD. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs. 2009;27:83-87. [PMID: 18563296 DOI: 10.1007/s10637-008-9146-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
254 Hurwitz H, Mitchell EP, Cartwright T, Kwok A, Hu S, McKenna E, Patt YZ. A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). Oncologist 2012;17:937-46. [PMID: 22622147 DOI: 10.1634/theoncologist.2012-0071] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
255 Jalaeikhoo H, Khajeh-Mehrizi A, Zokaasadi M, Rajaeinejad M, Asadollah Mousavi S, Vaezi M, Kamranzadeh Fumani H, Keyhani M, Alimoghaddam K, Ghavamzadeh A. Sixteen Years of Experience with the Treatment of Advanced Colorectal Cancer in Iran; A Report from Three Institutions. Middle East J Dig Dis 2018;10:160-8. [PMID: 30186579 DOI: 10.15171/mejdd.2018.105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
256 Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18. [DOI: 10.1038/nrclinonc.2009.110] [Cited by in Crossref: 257] [Cited by in F6Publishing: 224] [Article Influence: 19.8] [Reference Citation Analysis]
257 Rasco DW, Yan J, Xie Y, Dowell JE, Gerber DE. Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 2010;5:1529-35. [PMID: 20631635 DOI: 10.1097/JTO.0b013e3181e9a00f] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
258 Wang F, Wang FH, Bai L, Xu RH. Role of capecitabine in treating metastatic colorectal cancer in Chinese patients. Onco Targets Ther 2014;7:501-11. [PMID: 24729715 DOI: 10.2147/OTT.S38843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
259 Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, Kahn Y, Spira A, Dancey J, Iacobuzio-Donahue C, Donehower RC, Carducci M, Rudek MA, Hidalgo M. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer 2010;9:297-304. [PMID: 21208844 DOI: 10.3816/CCC.2010.n.043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
260 Desautels D, Harlos C, Czaykowski P. The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer. J Carcinog 2014;13:13. [PMID: 25525412 DOI: 10.4103/1477-3163.145609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
261 Wang T, Lin F, Sun X, Jiang L, Mao R, Zhou S, Shang W, Bi R, Lu F, Li S. HOXB8 enhances the proliferation and metastasis of colorectal cancer cells by promoting EMT via STAT3 activation. Cancer Cell Int 2019;19:3. [PMID: 30622439 DOI: 10.1186/s12935-018-0717-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
262 Haraldsdottir S, Wu C, Bloomston M, Goldberg RM. What is the optimal neo-adjuvant treatment for liver metastasis? Ther Adv Med Oncol. 2013;5:221-234. [PMID: 23858331 DOI: 10.1177/1758834013485111] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
263 Chibaudel B, Bonnetain F, Tournigand C, de Larauze MH, de Gramont A, Laurent-Puig P, Paget J, Hadengue A, Notelet D, Benetkiewicz M. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. BMC Cancer. 2015;15:496. [PMID: 26141683 DOI: 10.1186/s12885-015-1503-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
264 Cremolini C, Marmorino F, Loupakis F, Masi G, Antoniotti C, Salvatore L, Schirripa M, Boni L, Zagonel V, Lonardi S, Aprile G, Tamburini E, Ricci V, Ronzoni M, Pietrantonio F, Valsuani C, Tomasello G, Passardi A, Allegrini G, Di Donato S, Santini D, Falcone A; all the investigators of the Gruppo Oncologico del Nord Ovest. TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. BMC Cancer 2017;17:408. [PMID: 28599628 DOI: 10.1186/s12885-017-3360-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
265 Bhatt A, Goéré D. Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer. Indian J Surg Oncol 2016;7:177-87. [PMID: 27065708 DOI: 10.1007/s13193-016-0499-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
266 Rodriguez A, Esposito F, Oliveres H, Torres F, Maurel J. Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval? J Clin Med 2021;10:746. [PMID: 33668473 DOI: 10.3390/jcm10040746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Modest DP, Hiddemann W, Heinemann V. [Chemotherapy of metastatic colorectal cancer]. Internist (Berl) 2014;55:37-42. [PMID: 24399471 DOI: 10.1007/s00108-013-3314-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
268 Raskov H, Pommergaard HC, Burcharth J, Rosenberg J. Colorectal carcinogenesis-update and perspectives. World J Gastroenterol 2014; 20(48): 18151-18164 [PMID: 25561783 DOI: 10.3748/wjg.v20.i48.18151] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 90] [Article Influence: 11.3] [Reference Citation Analysis]
269 Stein A, Schmoll HJ. Systemic treatment of liver metastases from colorectal cancer. Ther Adv Med Oncol. 2013;5:193-203. [PMID: 23634197 DOI: 10.1177/1758834012473347] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
270 Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21:1381-1389. [PMID: 20538785 DOI: 10.1681/asn.2010020167] [Cited by in Crossref: 141] [Cited by in F6Publishing: 59] [Article Influence: 11.8] [Reference Citation Analysis]
271 An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB, Jiang YY. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 2010;66:813-21. [PMID: 20401474 DOI: 10.1007/s00228-010-0815-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
272 Kiss D, Machackova T, Souckova K, Fabian P, Krepelkova I, Svoboda M, Kiss I. An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer. In Vivo 2021;35:2809-14. [PMID: 34410972 DOI: 10.21873/invivo.12567] [Reference Citation Analysis]
273 Saif MW. Targeting cancers in the gastrointestinal tract: role of capecitabine. Onco Targets Ther 2009;2:29-41. [PMID: 20616892 DOI: 10.2147/ott.s3469] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
274 Zhu Y, Hanna N, Boutros C, Alexander HR Jr. Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases. J Gastrointest Oncol 2013;4:62-71. [PMID: 23450068 DOI: 10.3978/j.issn.2078-6891.2012.053] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
275 Seow HF, Yip WK, Fifis T. Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016;9:1899-920. [PMID: 27099521 DOI: 10.2147/OTT.S95101] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
276 Lau DK, Mencel J, Chau I. Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. Expert Opin Drug Saf 2022;:1-9. [PMID: 34986714 DOI: 10.1080/14740338.2022.2008905] [Reference Citation Analysis]
277 Chen CJ, McCoy AN, Brahmer J, Handa JT. Emerging treatments for choroidal metastases. Surv Ophthalmol 2011;56:511-21. [PMID: 22117885 DOI: 10.1016/j.survophthal.2011.05.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
278 Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C, Cohn A, Starodub A, Arrowood C, Haley S, Meadows KL, Morse MA, Uronis HE, Blobe GC, Hsu SD, Zafar SY, Hurwitz HI. Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Invest New Drugs 2014;32:330-9. [PMID: 24173967 DOI: 10.1007/s10637-013-0042-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
279 Barat A, Smeets D, Moran B, Zhang W, Cao S, Das S, Klinger R, Betge J, Murphy V, Bacon O, Kay EW, Van Grieken NCT, Verheul HMW, Gaiser T, Schulte N, Ebert MP, Fender B, Hennessy BT, McNamara DA, O'Connor D, Gallagher WM, Cremolini C, Loupakis F, Parikh A, Mancao C, Ylstra B, Lambrechts D, Lenz HJ, Byrne AT, Prehn JHM. Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. Sci Rep 2020;10:9778. [PMID: 32555399 DOI: 10.1038/s41598-020-65869-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
280 Tsofack SP, Garand C, Sereduk C, Chow D, Aziz M, Guay D, Yin HH, Lebel M. NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines. Mol Cancer 2011;10:145. [PMID: 22118625 DOI: 10.1186/1476-4598-10-145] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
281 Sasaki S, Oki E, Saeki H, Shimose T, Sakamoto S, Hu Q, Kudo K, Tsuda Y, Nakashima Y, Ando K, Akagi Y, Kakeji Y, Baba H, Maehara Y. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A). Int J Clin Oncol. 2019;24:1204-1213. [PMID: 31062115 DOI: 10.1007/s10147-019-01460-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
282 Yajima S, Shimizu H, Sakamaki H, Ikeda S, Ikegami N, Murayama JI. Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy. BMC Health Serv Res 2016;16:2. [PMID: 26728154 DOI: 10.1186/s12913-015-1253-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
283 Ma WH, An YH, Zhang YQ, Guo Y, Li N. Bevacizumab maintenance treatment for colorectal cancer: A meta-analysis. Shijie Huaren Xiaohua Zazhi 2017; 25(4): 340-350 [DOI: 10.11569/wcjd.v25.i4.340] [Reference Citation Analysis]
284 Kirstein MM, Lange A, Prenzler A, Manns MP, Kubicka S, Vogel A. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist. 2014;19:1156-1168. [PMID: 25326159 DOI: 10.1634/theoncologist.2014-0032] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 8.6] [Reference Citation Analysis]
285 Biondo S, Frago R, Kreisler E, Espin-Basany E; Spanish CR4 Group. Impact of resection versus no resection of the primary tumor on survival in patients with colorectal cancer and synchronous unresectable metastases: protocol for a randomized multicenter study (CR4). Int J Colorectal Dis 2017;32:1085-90. [PMID: 28497402 DOI: 10.1007/s00384-017-2827-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
286 Faïs T, Delmas J, Cougnoux A, Dalmasso G, Bonnet R. Targeting colorectal cancer-associated bacteria: A new area of research for personalized treatments. Gut Microbes 2016;7:329-33. [PMID: 27007710 DOI: 10.1080/19490976.2016.1155020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
287 Li D, Wang F, Xu S, Li K, Meng X, Huang Y, Ma N, Qiao L, Kuang G, Chen J, Liu Y. Continuing Cetuximab vs Bevacizumab plus chemotherapy after first progression in wild-type KRAS, NRAS and BRAF V600E metastatic colorectal cancer: a randomized phase II trial. J Cancer 2021;12:5268-74. [PMID: 34335943 DOI: 10.7150/jca.60014] [Reference Citation Analysis]
288 Kurimoto M, Kimura M, Usami E, Iwai M, Hirose T, Kawachi S, Yoshimura T. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer. Mol Clin Oncol 2017;7:125-30. [PMID: 28685089 DOI: 10.3892/mco.2017.1278] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
289 Glincher R, Price AP, LaQuaglia MP, Kushner BH, Modak S. Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma. J Pediatr Hematol Oncol 2018;40:e394-6. [PMID: 28816801 DOI: 10.1097/MPH.0000000000000940] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
290 Moriwaki T, Sakai Y, Ishida H, Yamamoto Y, Endo S, Kuramochi H, Sato M, Hatachi Y, Bando Y, Maeba T, Ikezawa K, Shimada M, Amagai K, Morimoto M, Kobayashi K, Tsuji A, Nishina T, Hyodo I. Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER). Int J Clin Oncol 2019;24:1214-22. [PMID: 31089842 DOI: 10.1007/s10147-019-01465-3] [Reference Citation Analysis]
291 Hwang IG, Kwon M, Kim JW, Kim SH, Lee YG, Kim JY, Koh SJ, Ko YH, Shin SH, Hong S, Kim TY, Kim SY, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Lee KH, Bae SH, Koo DH, Kim JH, Woo IS. Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. Cancers (Basel) 2021;13:331. [PMID: 33477423 DOI: 10.3390/cancers13020331] [Reference Citation Analysis]
292 Lindholm DP, Eriksson B, Granberg D. Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma. Med Oncol 2012;29:301-3. [PMID: 21191667 DOI: 10.1007/s12032-010-9789-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
293 Tsunekuni K, Konno M, Asai A, Koseki J, Kobunai T, Takechi T, Doki Y, Mori M, Ishii H. MicroRNA profiles involved in trifluridine resistance. Oncotarget 2017;8:53017-27. [PMID: 28881790 DOI: 10.18632/oncotarget.18078] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
294 Conley BA, Staudt L, Takebe N, Wheeler DA, Wang L, Cardenas MF, Korchina V, Zenklusen JC, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn E, Little RF, White J, Malik S, Harris LN, Mann B, Weil C, Tarnuzzer R, Karlovich C, Rodgers B, Shankar L, Jacobs PM, Nolan T, Berryman SM, Gastier-Foster J, Bowen J, Leraas K, Shen H, Laird PW, Esteller M, Miller V, Johnson A, Edmondson EF, Giordano TJ, Kim B, Ivy SP. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst 2021;113:27-37. [PMID: 32339229 DOI: 10.1093/jnci/djaa061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
295 Chong G, Tebbutt NC. Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Ther Adv Med Oncol 2010;2:309-17. [PMID: 21789143 DOI: 10.1177/1758834010375096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
296 Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, El-Rayes BF, Flowers CR. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol 2015;33:1112-8. [PMID: 25691669 DOI: 10.1200/JCO.2014.58.4904] [Cited by in Crossref: 97] [Cited by in F6Publishing: 49] [Article Influence: 13.9] [Reference Citation Analysis]
297 Gan Z, Zou Q, Lin Y, Xu Z, Huang Z, Chen Z, Lv Y. Identification of a 13-gene-based classifier as a potential biomarker to predict the effects of fluorouracil-based chemotherapy in colorectal cancer. Oncol Lett. 2019;17:5057-5063. [PMID: 31186717 DOI: 10.3892/ol.2019.10159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
298 Giampieri R, Puzzoni M, Daniele B, Ferrari D, Lonardi S, Zaniboni A, Cavanna L, Rosati G, Pella N, Zampino MG, Sozzi P, Germano D, Zagonel V, Codecà C, Libertini M, Labianca R, Cascinu S, Scartozzi M; Italian Group for the Study of Gastrointestinal Cancer (GISCAD). First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial. Br J Cancer 2017;117:1099-104. [PMID: 28926529 DOI: 10.1038/bjc.2017.234] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
299 Cao B, Li ST, Li Z, Deng WL. Yiqi zhuyu decoction combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer. Chin J Integr Med 2011;17:593-9. [PMID: 21826593 DOI: 10.1007/s11655-011-0822-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
300 Yang J, Ma Q, Zhang M, Zhang W. LncRNA CYTOR drives L-OHP resistance and facilitates the epithelial-mesenchymal transition of colon carcinoma cells via modulating miR-378a-5p/SERPINE1. Cell Cycle 2021;20:1415-30. [PMID: 34224332 DOI: 10.1080/15384101.2021.1934626] [Reference Citation Analysis]
301 Goi T, Nakazawa T, Hirono Y, Yamaguchi A. The anti-tumor effect is enhanced by simultaneously targeting VEGF and PROK1 in colorectal cancer. Oncotarget 2015;6:6053-61. [PMID: 25788276 DOI: 10.18632/oncotarget.3474] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
302 Cremolini C, Schirripa M, Antoniotti C, Moretto R, Salvatore L, Masi G, Falcone A, Loupakis F. First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat Rev Clin Oncol 2015;12:607-19. [PMID: 26215044 DOI: 10.1038/nrclinonc.2015.129] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 13.0] [Reference Citation Analysis]
303 Awazu Y, Mizutani A, Nagase Y, Tsuchiya S, Nakamura K, Kakoi Y, Kitahara O, Takeuchi T, Yamasaki S, Miyamoto N, Iwata H, Miki H, Imamura S, Hori A. Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase. Cancer Sci 2013;104:486-94. [PMID: 23305239 DOI: 10.1111/cas.12101] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
304 Kandioler D, Mittlböck M, Kappel S, Puhalla H, Herbst F, Langner C, Wolf B, Tschmelitsch J, Schippinger W, Steger G, Hofbauer F, Samonigg H, Gnant M, Teleky B, Kührer I; p53 Research Group and the Austrian Breast and Colorectal Study Group (ABCSG). TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients. EBioMedicine 2015;2:825-30. [PMID: 26425688 DOI: 10.1016/j.ebiom.2015.06.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
305 Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML, Grenga I, Schirru M, Guadagni F, Roselli M. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis 2011;26:143-51. [PMID: 21188390 DOI: 10.1007/s00384-010-1108-1] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
306 Mohile SG, Hardt M, Tew W, Owusu C, Klepin H, Gross C, Gajra A, Lichtman SM, Feng T, Togawa K, Ramani R, Katheria V, Hansen K, Hurria A; Cancer and Aging Research Group. Toxicity of bevacizumab in combination with chemotherapy in older patients. Oncologist 2013;18:408-14. [PMID: 23576485 DOI: 10.1634/theoncologist.2012-0351] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
307 Lubner SJ, Uboha NV, Deming DA. Primary and acquired resistance to biologic therapies in gastrointestinal cancers. J Gastrointest Oncol 2017;8:499-512. [PMID: 28736637 DOI: 10.21037/jgo.2017.01.16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
308 Sugihara K, Ohtsu A, Shimada Y, Mizunuma N, Lee PH, de Gramont A, Goldberg RM, Rothenberg ML, André T, Brienza S, Gomi K. Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. Clin Colorectal Cancer 2012;11:127-37. [PMID: 22099928 DOI: 10.1016/j.clcc.2011.09.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
309 Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig 2010;30:229-41. [PMID: 20225906 DOI: 10.2165/11532260-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
310 Rodriguez-Pascual J, Cubillo A. Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review. Curr Pharmacogenomics Person Med 2017;15:81-5. [PMID: 29657584 DOI: 10.2174/1875692115666170815161754] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
311 Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Chin K, Yamaguchi T. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Drug Des Devel Ther 2015;9:1653-62. [PMID: 25834402 DOI: 10.2147/DDDT.S80449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
312 Folprecht G. [Current medicinal treatment of metastasized colorectal carcinoma]. Chirurg. 2010;81:507-515. [PMID: 20574792 DOI: 10.1007/s00104-010-1892-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
313 Kimura M, Usami E, Iwai M, Go M, Teramachi H, Yoshimura T. Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer. Mol Clin Oncol 2016;5:635-40. [PMID: 27900102 DOI: 10.3892/mco.2016.1020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
314 Binefa G, Rodríguez-Moranta F, Teule &, Medina-Hayas M. Colorectal cancer: From prevention to personalized medicine. World J Gastroenterol 2014; 20(22): 6786-6808 [PMID: 24944469 DOI: 10.3748/wjg.v20.i22.6786] [Cited by in CrossRef: 155] [Cited by in F6Publishing: 145] [Article Influence: 19.4] [Reference Citation Analysis]
315 Temraz S, Mukherji D, Shamseddine A. Sequencing of treatment in metastatic colorectal cancer: Where to fit the target? World J Gastroenterol 2014; 20(8): 1993-2004 [PMID: 24616571 DOI: 10.3748/wjg.v20.i8.1993] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
316 Han J, Xiao D, Tan C, Zeng X, Hu H, Zeng S, Jiang Q, She L, Yao L, Li L, Tang L, Ma J, Huang J, Shen L. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. Cancer Control 2020;27:1073274820902271. [PMID: 32107929 DOI: 10.1177/1073274820902271] [Reference Citation Analysis]
317 Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, Bossi P, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS;  Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer; 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-4074. [PMID: 27344327 DOI: 10.1007/s00520-016-3310-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
318 Pommier AJ, Shaw R, Spencer SK, Morgan SR, Hoff PM, Robertson JD, Barry ST, Jürgensmeier JM. Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib. Br J Cancer 2014;111:1590-604. [PMID: 25121956 DOI: 10.1038/bjc.2014.436] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
319 Kim YE, Joo B, Park MS, Shin SJ, Ahn JB, Kim MJ. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial. Cancer Res Treat. 2016;48:1210-1221. [PMID: 26987390 DOI: 10.4143/crt.2015.374] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
320 Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martínez-Cardús A, Marín-Aguilera M, Horndler C, Martínez-Balibrea E, Rubini M, Jares P, Reig O, Victoria I, Gaba L, Martín-Richard M, Alonso V, Escudero P, Fernández-Martos C, Feliu J, Méndez JC, Méndez M, Gallego J, Salud A, Rojo F, Castells A, Prat A, Rosell R, García-Albéniz X, Camps J, Maurel J. Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. Br J Cancer 2017;117:1777-86. [PMID: 29123263 DOI: 10.1038/bjc.2017.279] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
321 Hu X, Jiang Z, Teng L, Yang H, Hong D, Zheng D, Zhao Q. Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems. Front Mol Biosci 2021;8:770808. [PMID: 34901160 DOI: 10.3389/fmolb.2021.770808] [Reference Citation Analysis]
322 Razenberg LG, van Gestel YR, de Hingh IH, Loosveld OJ, Vreugdenhil G, Beerepoot LV, Creemers GJ, Lemmens VE. Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice. BMC Cancer 2016;16:110. [PMID: 26882902 DOI: 10.1186/s12885-016-2158-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
323 Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Yamaguchi T. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther 2015;9:3099-108. [PMID: 26124634 DOI: 10.2147/DDDT.S85567] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
324 Shimura T, Kataoka H, Hirata Y, Mizushima T, Murakami K, Mabuchi M, Mizoshita T, Kubota E, Tanida S, Kamiya T, Joh T. Metastatic colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy. J Gastrointest Cancer 2011;42:68-72. [PMID: 20563895 DOI: 10.1007/s12029-010-9176-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
325 Bacalbasa N, Balescu I, Cretoiu D, Halmaciu I, Dimitriu M, Socea B, Diaconu C, Iliescu L, Savu C, Savu C, Filipescu A, Stoica C, Stiru O. Determination of whether HIPEC is beneficial in patients with synchronous peritoneal and liver metastases from colorectal cancer (Review). Exp Ther Med 2021;22:1267. [PMID: 34594404 DOI: 10.3892/etm.2021.10702] [Reference Citation Analysis]
326 Strickler JH, Rushing CN, Niedzwiecki D, McLeod A, Altomare I, Uronis HE, Hsu SD, Zafar SY, Morse MA, Chang DZ, Wells JL, Blackwell KL, Marcom PK, Arrowood C, Bolch E, Haley S, Rangwala FA, Hatch AJ, Nixon AB, Hurwitz HI. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. BMC Cancer 2019;19:1032. [PMID: 31675952 DOI: 10.1186/s12885-019-6234-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
327 Saman H, Raza SS, Uddin S, Rasul K. Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches. Cancers (Basel) 2020;12:E1172. [PMID: 32384792 DOI: 10.3390/cancers12051172] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
328 Liang YH, Shao YY, Chen JY, Liang PC, Cheng AL, Lin ZZ. Modern prospection for hepatic arterial infusion chemotherapy in malignancies with liver metastases. Int J Hepatol 2013;2013:141590. [PMID: 23691329 DOI: 10.1155/2013/141590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
329 López-Gómez M, Cejas P, Merino M, Fernández-Luengas D, Casado E, Feliu J. Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment? Clin Transl Oncol 2012;14:641-58. [PMID: 22911546 DOI: 10.1007/s12094-012-0853-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
330 Rosati G, Cordio S, Aprile G, Butera A, Avallone A, Di Lucca G, De Pauli F, Parra HS, Reggiardo G, Bordonaro R. Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study. Invest New Drugs. 2012;30:1978-1983. [PMID: 21769636 DOI: 10.1007/s10637-011-9721-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
331 Tsai HT, Marshall JL, Weiss SR, Huang CY, Warren JL, Freedman AN, Fu AZ, Sansbury LB, Potosky AL. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol 2013;24:1574-9. [PMID: 23429865 DOI: 10.1093/annonc/mdt019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
332 Li T, Wang B, Wang Z, Ragaz J, Zhang J, Sun S, Cao J, Lv F, Wang L, Zhang S, Ni C, Wu Z, Xie J, Hu X. Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. PLoS One 2015;10:e0133133. [PMID: 26186012 DOI: 10.1371/journal.pone.0133133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
333 Maeda K, Shibutani M, Otani H, Nagahara H, Sugano K, Ikeya T, Kubo N, Amano R, Kimura K, Muguruma K. Low nutritional prognostic index correlates with poor survival in patients with stage IV colorectal cancer following palliative resection of the primary tumor. World J Surg. 2014;38:1217-1222. [PMID: 24305937 DOI: 10.1007/s00268-013-2386-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
334 Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamata H, Koisumi J. Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer. Surg Today 2013;43:1088-94. [PMID: 23143145 DOI: 10.1007/s00595-012-0416-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
335 Marisi G, Scarpi E, Passardi A, Nanni O, Ragazzini A, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P. Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab. Sci Rep. 2017;7:1293. [PMID: 28465540 DOI: 10.1038/s41598-017-01420-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
336 García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin Cancer Res 2015;21:5499-510. [PMID: 26272063 DOI: 10.1158/1078-0432.CCR-14-3091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
337 Jagieła J, Bartnicki P, Rysz J. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. Int J Mol Sci 2021;22:4618. [PMID: 33924827 DOI: 10.3390/ijms22094618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Zhao Z, Pelletier E, Barber B, Bhosle M, Wang S, Klingman D, Gao S. Major surgery in patients with metastatic colorectal cancer in Western europe. J Gastrointest Cancer 2012;43:456-61. [PMID: 22125088 DOI: 10.1007/s12029-011-9349-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
339 Conti RM, Rosenthal MB, Polite BN, Bach PB, Shih YC. Infused chemotherapy use in the elderly after patent expiration. J Oncol Pract 2012;8:e18s-23s. [PMID: 22942829 DOI: 10.1200/JOP.2012.000541] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
340 Osawa H. Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancer. Mol Clin Oncol 2017;6:365-72. [PMID: 28451414 DOI: 10.3892/mco.2017.1145] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
341 Battaglin F, Puccini A, Intini R, Schirripa M, Ferro A, Bergamo F, Lonardi S, Zagonel V, Lenz HJ, Loupakis F. The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Rev Anticancer Ther 2018;18:251-66. [PMID: 29338550 DOI: 10.1080/14737140.2018.1428092] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
342 Jang HJ, Kim BJ, Kim JH, Kim HS. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Oncotarget. 2017;8:73009-73016. [PMID: 29069844 DOI: 10.18632/oncotarget.20314] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
343 Bester L, Meteling B, Boshell D, Saxena A, Morris DL. Current role of transarterial chemoembolization and radioembolization in the treatment of metastatic colorectal cancer. Hepat Oncol 2014;1:215-28. [PMID: 30190956 DOI: 10.2217/hep.13.21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
344 Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C. Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice. Onco Targets Ther 2019;12:2159-70. [PMID: 30988620 DOI: 10.2147/OTT.S194745] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
345 Stathopoulos J, Armakolas A, Stathopoulos GP, Gomatos IP. Plasma VEGF levels in breast cancer patients with and without metastases. Oncol Lett 2010;1:739-41. [PMID: 22966372 DOI: 10.3892/ol_00000129] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
346 Toumazis I, Kurt M, Toumazi A, Karacosta LG, Kwon C. Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer. MDM Policy Pract 2017;2:2381468317729650. [PMID: 30288431 DOI: 10.1177/2381468317729650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
347 Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open 2016;1:e000066. [PMID: 27843624 DOI: 10.1136/esmoopen-2016-000066] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
348 Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer. Biologics 2014;8:13-25. [PMID: 24368879 DOI: 10.2147/BTT.S39360] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
349 Nomiya T, Akamatsu H, Harada M, Ota I, Hagiwara Y, Ichikawa M, Miwa M, Kawashiro S, Hagiwara M, Chin M, Hashizume E, Nemoto K. Modified simultaneous integrated boost radiotherapy for an unresectable huge refractory pelvic tumor diagnosed as a rectal adenocarcinoma. World J Gastroenterol 2014; 20(48): 18480-18486 [PMID: 25561820 DOI: 10.3748/wjg.v20.i48.18480] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
350 Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol 2011;5:89-99. [PMID: 21603244 DOI: 10.4137/CMO.S6983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
351 Burotto M, Hartley ML, Marshall JL, Pishvaian MJ. Future of targeted agents in metastatic colorectal cancer. Colorectal Cancer 2012;1. [PMID: 24273599 DOI: 10.2217/crc.12.52] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
352 Qu YL, Saifuding•Keyoumu, Tang Y. Efficacy and safety of bevacizumab combined with chemotherapy in treatment of metastatic colorectal cancer. Shijie Huaren Xiaohua Zazhi 2016; 24(17): 2748-2754 [DOI: 10.11569/wcjd.v24.i17.2748] [Reference Citation Analysis]
353 Lakatos G, Tulassay Z. [Antiangiogenic therapy for gastrointestinal tumors]. Orv Hetil 2008;149:2317-24. [PMID: 19042183 DOI: 10.1556/OH.2008.28496] [Reference Citation Analysis]
354 Kawagoe S, Nakano M, Uchino K, Arimizu K, Kajitani T, Shimokawa H, Kusumoto T, Ikejiri K, Baba E. Analysis of Response Evaluation Criteria in Solid Tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer. Mol Clin Oncol 2019;11:243-51. [PMID: 31396385 DOI: 10.3892/mco.2019.1894] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
355 Stein A, Bokemeyer C. How to select the optimal treatment for first line metastatic colorectal cancer. World J Gastroenterol 2014; 20(4): 899-907 [PMID: 24574764 DOI: 10.3748/wjg.v20.i4.899] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
356 Jang KU, Kim CW, Kim KH, Lim SB, Yu CS, Kim TW, Kim PN, Kim JH, Kim JC. Prognostic Factors in Terms of the Number of Metastatic Nodules in Patients With Colorectal Cancer Liver Metastases. Ann Coloproctol 2016;32:92-100. [PMID: 27437390 DOI: 10.3393/ac.2016.32.3.92] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
357 Tang R, Kain T, Herman J, Seery T. Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. Cancer Manag Res 2015;7:357-60. [PMID: 26640390 DOI: 10.2147/CMAR.S91547] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
358 Inoue Y, Hazama S, Suzuki N, Tokumitsu Y, Kanekiyo S, Tomochika S, Tsunedomi R, Tokuhisa Y, Iida M, Sakamoto K, Takeda S, Ueno T, Yoshino S, Nagano H. Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. Cancer Sci 2017;108:455-60. [PMID: 28075526 DOI: 10.1111/cas.13162] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
359 de Figueiredo Junior AG, Serafim PVP, de Melo AA, Felipe AV, Lo Turco EG, da Silva IDCG, Forones NM. Analysis of the Lipid Profile in Patients with Colorectal Cancer in Advanced Stages. Asian Pac J Cancer Prev 2018;19:1287-93. [PMID: 29802561 DOI: 10.22034/APJCP.2018.19.5.1287] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
360 Saif MW. Management of a patient with metastatic colorectal cancer and liver metastases. Case Rep Oncol Med 2014;2014:790192. [PMID: 24744930 DOI: 10.1155/2014/790192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
361 Song Y, Fu Y, Xie Q, Zhu B, Wang J, Zhang B. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Front Immunol 2020;11:1956. [PMID: 32983126 DOI: 10.3389/fimmu.2020.01956] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
362 Giakoustidis A, Neofytou K, Khan A, Mudan S. Addition of bevacizumab to preoperative chemotherapy for colorectal liver metastases does not increase perioperative morbidity and mortality. Hepat Oncol 2014;1:363-75. [PMID: 30190972 DOI: 10.2217/hep.14.17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
363 Arata R, Itamoto T, Ikeda S, Nakahara H, Oshita A, Shinozaki K, Nishisaka T. Pathological complete response after neoadjuvant chemotherapy for rectal cancer with synchronous multiple liver metastases: a report of an unusual case. Surg Case Rep 2016;2:106. [PMID: 27686666 DOI: 10.1186/s40792-016-0231-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
364 Wu B, Yang JK, Zhu YJ. Conversion therapy for colorectal cancer patients with potentially resectable liver metastases. Shijie Huaren Xiaohua Zazhi 2014; 22(4): 533-540 [DOI: 10.11569/wcjd.v22.i4.533] [Reference Citation Analysis]
365 Kyutoku M, Nakagami H, Koriyama H, Tomioka H, Nakagami F, Shimamura M, Kurinami H, Zhengda P, Jo DH, Kim JH, Takakura N, Morishita R. Development of novel DNA vaccine for VEGF in murine cancer model. Sci Rep 2013;3:3380. [PMID: 24287585 DOI: 10.1038/srep03380] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
366 Suzuki K, Takaharu K, Muto Y, Ichida K, Fukui T, Takayama Y, Tsujinaka S, Sasaki J, Horie H, Kawamura YJ, Konishi F, Rikiyama T. XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second-line setting involving the sequential administration of XELOX and XELIRI. Mol Clin Oncol 2014;2:827-32. [PMID: 25054053 DOI: 10.3892/mco.2014.306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
367 Hirose K, Oki E, Shimose T, Sakamoto S, Sasaki S, Jogo T, Hu Q, Tsuda Y, Ando K, Nakashima Y, Saeki H, Mori M. Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials. Int J Clin Oncol 2019;24:1397-405. [PMID: 31332611 DOI: 10.1007/s10147-019-01509-8] [Reference Citation Analysis]
368 Rong Z, Martel G, Vandenbroucke-Menu F, Adam R, Lapointe R. Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey. HPB (Oxford) 2014;16:342-9. [PMID: 24641317 DOI: 10.1111/hpb.12138] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
369 Shibutani M, Maeda K, Nagahara H, Ohtani H, Sakurai K, Yamazoe S, Kimura K, Toyokawa T, Amano R, Tanaka H, Muguruma K, Hirakawa K. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer. World J Gastroenterol 2015; 21(34): 9966-9973 [PMID: 26379401 DOI: 10.3748/wjg.v21.i34.9966] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
370 Kerr DJ, Young AM. Targeted therapies: bevacizumab--has it reached its final resting place? Nat Rev Clin Oncol 2011;8:195-6. [PMID: 21386819 DOI: 10.1038/nrclinonc.2011.32] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
371 Elfiky AA, Pany MJ, Parikh RB, Obermeyer Z. Development and Application of a Machine Learning Approach to Assess Short-term Mortality Risk Among Patients With Cancer Starting Chemotherapy. JAMA Netw Open 2018;1:e180926. [PMID: 30646043 DOI: 10.1001/jamanetworkopen.2018.0926] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
372 Siegelmann-Danieli N, Farkash A, Katzir I, Vesterman Landes J, Rotem Rabinovich H, Lomnicky Y, Carmeli B, Parush-Shear-Yashuv N. A Novel Computational Tool for Mining Real-Life Data: Application in the Metastatic Colorectal Cancer Care Setting. PLoS One 2016;11:e0154689. [PMID: 27144545 DOI: 10.1371/journal.pone.0154689] [Reference Citation Analysis]
373 Dotan E, Meropol NJ, Zhu F, Zambito F, Bove B, Cai KQ, Godwin AK, Golemis EA, Astsaturov I, Cohen SJ. Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer. Br J Cancer 2012;106:748-55. [PMID: 22240781 DOI: 10.1038/bjc.2011.587] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
374 Artaç M, Coşkun HŞ, Dane F, Karabulut B, Korkmaz L, Karaağaç M, Çabuk D, Karabulut S, Faruk Aykan N, Doruk H, Avcı N, Turhal NS. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. J Gastrointest Cancer 2016;47:264-72. [PMID: 27126591 DOI: 10.1007/s12029-016-9823-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
375 Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102:8-18. [PMID: 20010945 DOI: 10.1038/sj.bjc.6605483] [Cited by in Crossref: 162] [Cited by in F6Publishing: 148] [Article Influence: 12.5] [Reference Citation Analysis]
376 Kawasaki A, Mimatsu K, Oida T, Kanou H, Kuboi Y, Fukino N, Kida K, Amano S. A case of long partial response to combination therapy of bevacizumab and capecitabine for liver metastases of rectal cancer. Case Rep Gastroenterol 2011;5:28-32. [PMID: 21326855 DOI: 10.1159/000323138] [Reference Citation Analysis]
377 Pawlik TM, Cosgrove D. The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? J Gastrointest Surg. 2011;15:410-415. [PMID: 21253876 DOI: 10.1007/s11605-011-1423-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
378 Foster B, Wagman LD. Surgical Stress-Induced Oxaliplatin-Associated Interstitial Pneumonitis. The American Surgeon 2011;77:272-3. [DOI: 10.1177/000313481107701206] [Reference Citation Analysis]
379 Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28:453-459. [PMID: 20008624 DOI: 10.1200/jco.2009.24.8252] [Cited by in Crossref: 347] [Cited by in F6Publishing: 168] [Article Influence: 26.7] [Reference Citation Analysis]
380 Gao X, Sanderson SM, Dai Z, Reid MA, Cooper DE, Lu M, Richie JP Jr, Ciccarella A, Calcagnotto A, Mikhael PG, Mentch SJ, Liu J, Ables G, Kirsch DG, Hsu DS, Nichenametla SN, Locasale JW. Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature 2019;572:397-401. [PMID: 31367041 DOI: 10.1038/s41586-019-1437-3] [Cited by in Crossref: 174] [Cited by in F6Publishing: 155] [Article Influence: 58.0] [Reference Citation Analysis]
381 Abair T, Xu B, Ranganathan A, Quill T, Chu E, Cunningham D. The Annual Meeting of the American Society of Clinical Oncology. Clinical Colorectal Cancer 2010;9:195-204. [DOI: 10.3816/ccc.2010.n.029] [Reference Citation Analysis]
382 Clarke JM, Hurwitz HI. Ziv-aflibercept: binding to more than VEGF-A--does more matter? Nat Rev Clin Oncol 2013;10:10-1. [PMID: 23149898 DOI: 10.1038/nrclinonc.2012.197] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
383 Ronnekleiv-Kelly SM, Burkhart RA, Pawlik TM. Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. Surg Oncol 2016;25:190-9. [PMID: 27566022 DOI: 10.1016/j.suronc.2016.05.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
384 Torres OJ, Marques MC, Santos FN, Farias IC, Coutinho AK, Oliveira CV, Kalil AN, Mello CA, Kruger JA, Fernandes GD, Quireze C Jr, Murad AM, Silva MJ, Zurstrassen CE, Freitas HC, Cruz MR, Weschenfelder R, Linhares MM, Castro LD, Vollmer C, Dixon E, Ribeiro HS, Coimbra FJ. BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES. Arq Bras Cir Dig 2016;29:173-9. [PMID: 27759781 DOI: 10.1590/0102-6720201600030011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
385 Shamimi-Noori S, Gonsalves CF, Shaw CM. Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data.Semin Intervent Radiol. 2017;34:145-166. [PMID: 28579683 DOI: 10.1055/s-0037-1602712] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
386 Poon C, He C, Liu D, Lu K, Lin W. Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer. J Control Release 2015;201:90-9. [PMID: 25620067 DOI: 10.1016/j.jconrel.2015.01.026] [Cited by in Crossref: 87] [Cited by in F6Publishing: 80] [Article Influence: 12.4] [Reference Citation Analysis]
387 Ciombor KK, Berlin J. Targeting metastatic colorectal cancer - present and emerging treatment options. Pharmgenomics Pers Med 2014;7:137-44. [PMID: 25045279 DOI: 10.2147/PGPM.S47582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
388 Zhao Y, Yu X, Li J. Manipulation of immune‒vascular crosstalk: new strategies towards cancer treatment. Acta Pharm Sin B 2020;10:2018-36. [PMID: 33304777 DOI: 10.1016/j.apsb.2020.09.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
389 Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009;101:1033-8. [PMID: 19789532 DOI: 10.1038/sj.bjc.6605259] [Cited by in Crossref: 128] [Cited by in F6Publishing: 106] [Article Influence: 9.8] [Reference Citation Analysis]
390 Wiegering A, Korb D, Thalheimer A, Kämmerer U, Allmanritter J, Matthes N, Linnebacher M, Schlegel N, Klein I, Ergün S, Germer CT, Otto C. E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts. Neoplasia 2014;16:972-81. [PMID: 25425971 DOI: 10.1016/j.neo.2014.09.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
391 Jackson CG, Sharples K, Thompson PI, O'Donnell A, Robinson BA, Perez DJ, Adams J, Isaacs R, Deva S, Hinder VA, Findlay MP. Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. BMC Cancer 2014;14:737. [PMID: 25274181 DOI: 10.1186/1471-2407-14-737] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
392 Peng Y, Chen Y, Zhang X, Yang Y, Cao D, Bi F, Li Z, Gou H. Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy. J Cancer Res Clin Oncol 2018;144:1339-46. [PMID: 29774414 DOI: 10.1007/s00432-018-2656-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
393 Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X. An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One 2014;9:e89960. [PMID: 24599121 DOI: 10.1371/journal.pone.0089960] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
394 Xu JL, Tang CW, Feng WM, Bao Y, Chai ZZ. Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection. Med Sci Monit 2019;25:4831-6. [PMID: 31254462 DOI: 10.12659/MSM.915992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
395 Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist 2010;15:683-94. [PMID: 20547589 DOI: 10.1634/theoncologist.2009-0235] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
396 Ramjeesingh R, Meyer RM, Brouwers M, Chen BE, Booth CM. Alignment of practice guidelines with targeted-therapy drug funding policies in Ontario. Curr Oncol 2013;20:e21-33. [PMID: 23444033 DOI: 10.3747/co.20.1166] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
397 Pan CF, Zhang X, Wang JW, Yang T, Zhong LLD, Shen KP. Weichang'an Formula Inhibits Tumor Growth in Combination with Bevacizumab in a Murine Model of Colon Cancer-Making up for the Deficiency of Bevacizumab by inhibiting VEGFR-1. Front Pharmacol 2020;11:512598. [PMID: 33746736 DOI: 10.3389/fphar.2020.512598] [Reference Citation Analysis]
398 Tamiya A, Yamazaki K, Boku N, Machida N, Kojima T, Taku K, Yasui H, Fukutomi A, Hironaka S, Onozawa Y. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. Int J Clin Oncol. 2009;14:513-517. [PMID: 19967487 DOI: 10.1007/s10147-009-0911-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
399 Heath EI, Blumenschein GR Jr, Cohen RB, Lorusso PM, Loconte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemother Pharmacol 2011;68:703-12. [PMID: 21140147 DOI: 10.1007/s00280-010-1536-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
400 Qadan M, D'Angelica MI. Complex Surgical Strategies to Improve Resectability in Borderline-Resectable Disease. Curr Colorectal Cancer Rep. 2015;11:369-377. [PMID: 28090195 DOI: 10.1007/s11888-015-0290-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
401 Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-3683. [PMID: 19470929 DOI: 10.1200/jco.2008.20.5278] [Cited by in Crossref: 819] [Cited by in F6Publishing: 381] [Article Influence: 63.0] [Reference Citation Analysis]
402 Sullivan R, Pramesh CS, Booth CM. Cancer patients need better care, not just more technology. Nature 2017;549:325-8. [PMID: 28933447 DOI: 10.1038/549325a] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
403 Simoneau E, Chicoine J, Negi S, Salman A, Lazaris A, Hassanain M, Beauchemin N, Petrillo S, Valenti D, Amre R, Metrakos P. Next generation sequencing of progressive colorectal liver metastases after portal vein embolization. Clin Exp Metastasis 2017;34:351-61. [PMID: 28758175 DOI: 10.1007/s10585-017-9855-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
404 Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Vera R, Serra O, Casado E, Jorge M, Escudero P, Bosch C, Bohn U, Pérez-Carrión R, Carmona A, Martínez-Marín V, Maurel J. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. Br J Cancer 2014;111:241-8. [PMID: 24946000 DOI: 10.1038/bjc.2014.346] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
405 Bécouarn Y, Cany L, Pulido M, Beyssac R, Texereau P, Le Morvan V, Béchade D, Brunet R, Aitouferoukh S, Lalet C, Mathoulin-Pélissier S, Fonck M, Robert J. FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC Res Notes 2014;7:260. [PMID: 24758527 DOI: 10.1186/1756-0500-7-260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
406 Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011;17:6130-6139. [PMID: 21953501 DOI: 10.1158/1078-0432.ccr-11-0659] [Cited by in Crossref: 196] [Cited by in F6Publishing: 100] [Article Influence: 17.8] [Reference Citation Analysis]
407 Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One 2013;8:e51780. [PMID: 23349675 DOI: 10.1371/journal.pone.0051780] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
408 Takemura N, Saiura A, Koga R, Arita J, Yoshioka R, Ono Y, Hiki N, Sano T, Yamamoto J, Kokudo N, Yamaguchi T. Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg 2012;397:951-7. [PMID: 22615045 DOI: 10.1007/s00423-012-0959-z] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 8.3] [Reference Citation Analysis]
409 Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist 2010;15:819-25. [PMID: 20688807 DOI: 10.1634/theoncologist.2009-0317] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 6.3] [Reference Citation Analysis]
410 Ghiringhelli F, Bichard D, Limat S, Lorgis V, Vincent J, Borg C, Berthou J, Orry D, Ortega-Deballon P, Lakkis Z, Facy O, Heyd B, Rat P, Nerich V, Ladoire S. Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection. Ann Surg Oncol 2014;21:1632-40. [PMID: 24419756 DOI: 10.1245/s10434-013-3463-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
411 Maeda K, Shibutani M, Otani H, Nagahara H, Ikeya T, Iseki Y, Tanaka H, Muguruma K, Hirakawa K. Inflammation-based factors and prognosis in patients with colorectal cancer. World J Gastrointest Oncol 2015; 7(8): 111-117 [PMID: 26306143 DOI: 10.4251/wjgo.v7.i8.111] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
412 Dai F, Shu L, Bian Y, Wang Z, Yang Z, Chu W, Gao S. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials. Clin Drug Investig. 2013;33:779-788. [PMID: 23979925 DOI: 10.1007/s40261-013-0125-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
413 Feng W, Wang Y, Zhu X. Baseline serum lactate dehydrogenase level predicts survival benefit in patients with metastatic colorectal cancer receiving bevacizumab as first-line chemotherapy: a systematic review and meta-analysis of 7 studies and 1,219 patients. Ann Transl Med 2019;7:133. [PMID: 31157254 DOI: 10.21037/atm.2019.02.45] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
414 Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21. [PMID: 21364524 DOI: 10.1038/nrclinonc.2011.21] [Cited by in Crossref: 474] [Cited by in F6Publishing: 447] [Article Influence: 43.1] [Reference Citation Analysis]
415 Zhao T, Wang X, Xu T, Xu X, Liu Z. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget. 2017;8:51492-51506. [PMID: 28881662 DOI: 10.18632/oncotarget.18190] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
416 Hagan S, Orr MC, Doyle B. Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J 2013;4:3. [PMID: 23356214 DOI: 10.1186/1878-5085-4-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
417 Moritani K, Kanemitsu Y, Shida D, Shitara K, Mizusawa J, Katayama H, Hamaguchi T, Shimada Y; Colorectal Cancer Study Group (CCSG) of Japan Clinical Oncology Group (JCOG). A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study). Jpn J Clin Oncol. 2020;50:89-93. [PMID: 31829404 DOI: 10.1093/jjco/hyz173] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
418 De Pasquale MD, Crocoli A, Caldaro T, Rinelli M, Spinelli GP, Francalanci P, Cozza R, Inserra A, Miele E. Targeting Epidermal Growth Factor Receptor (EGFR) in Pediatric Colorectal Cancer. Cancers (Basel) 2020;12:E414. [PMID: 32053874 DOI: 10.3390/cancers12020414] [Reference Citation Analysis]
419 Goldstein DA, Chen Q, Ayer T, Chan KKW, Virik K, Hammerman A, Brenner B, Flowers CR, Hall PS. Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. Oncologist 2017;22:694-9. [PMID: 28592621 DOI: 10.1634/theoncologist.2016-0455] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
420 Lisby AN, Flickinger JC Jr, Bashir B, Weindorfer M, Shelukar S, Crutcher M, Snook AE, Waldman SA. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Rev Precis Med Drug Dev 2021;6:117-29. [PMID: 34027103 DOI: 10.1080/23808993.2021.1876518] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
421 Algazi AP, Cha E, Ortiz-Urda SM, McCalmont T, Bastian BC, Hwang J, Pampaloni MH, Behr S, Chong K, Cortez B, Quiroz A, Coakley F, Liu S, Daud AI. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. Br J Cancer 2015;112:1326-31. [PMID: 25867272 DOI: 10.1038/bjc.2014.541] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
422 Grothey A, Allegra C. Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:301-319. [PMID: 23118806 DOI: 10.1177/1758834012454464] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
423 Yoshida M, Shimura T, Sato M, Ebi M, Nakazawa T, Takeyama H, Joh T. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. J Cancer Res Clin Oncol 2013;139:367-78. [PMID: 23099994 DOI: 10.1007/s00432-012-1340-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
424 Price TJ, Bruhn MA, Lee CK, Hardingham JE, Townsend AR, Mann KP, Simes J, Weickhardt A, Wrin JW, Wilson K. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. Br J Cancer. 2015;112:963-970. [PMID: 25742472 DOI: 10.1038/bjc.2015.37] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
425 Hocking CM, Price TJ. Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. Therap Adv Gastroenterol. 2014;7:20-37. [PMID: 24381645 DOI: 10.1177/1756283x13498660] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
426 Silberhumer GR, Paty PB, Denton B, Guillem J, Gonen M, Araujo RLC, Nash GM, Temple LK, Allen PJ, DeMatteo RP, Weiser MR, Wong WD, Jarnagin WR, D'Angelica MI, Fong Y. Long-term oncologic outcomes for simultaneous resection of synchronous metastatic liver and primary colorectal cancer. Surgery. 2016;160:67-73. [PMID: 27079362 DOI: 10.1016/j.surg.2016.02.029] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
427 Cisterna BA, Kamaly N, Choi WI, Tavakkoli A, Farokhzad OC, Vilos C. Targeted nanoparticles for colorectal cancer. Nanomedicine (Lond) 2016;11:2443-56. [PMID: 27529192 DOI: 10.2217/nnm-2016-0194] [Cited by in Crossref: 66] [Cited by in F6Publishing: 54] [Article Influence: 11.0] [Reference Citation Analysis]
428 Lu J, Ye X, Fan F, Xia L, Bhattacharya R, Bellister S, Tozzi F, Sceusi E, Zhou Y, Tachibana I, Maru DM, Hawke DH, Rak J, Mani SA, Zweidler-McKay P, Ellis LM. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell. 2013;23:171-185. [PMID: 23375636 DOI: 10.1016/j.ccr.2012.12.021] [Cited by in Crossref: 278] [Cited by in F6Publishing: 254] [Article Influence: 30.9] [Reference Citation Analysis]
429 Zulato E, Bergamo F, De Paoli A, Griguolo G, Esposito G, De Salvo GL, Mescoli C, Rugge M, Nardin M, Di Grazia L, Lonardi S, Indraccolo S, Zagonel V. Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. Br J Cancer 2014;111:25-32. [PMID: 24892446 DOI: 10.1038/bjc.2014.274] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
430 Kim BJ, Jeong JH, Kim JH, Kim HS, Jang HJ. The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review. Oncotarget 2017;8:31112-8. [PMID: 28415706 DOI: 10.18632/oncotarget.16091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
431 Nipp RD, Ryan DP. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer? Oncologist 2015;20:236-8. [PMID: 25660156 DOI: 10.1634/theoncologist.2014-0495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
432 Ketchart W, Smith KM, Krupka T, Wittmann BM, Hu Y, Rayman PA, Doughman YQ, Albert JM, Bai X, Finke JH, Xu Y, Exner AA, Montano MM. Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis. Oncogene 2013;32:3829-39. [PMID: 22964639 DOI: 10.1038/onc.2012.405] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
433 Koukourakis GV, Zacharias G, Tsalafoutas J, Theodoridis D, Kouloulias V. Capecitabine for locally advanced and metastatic colorectal cancer: A review. World J Gastrointest Oncol 2010; 2(8): 311-321 [PMID: 21160892 DOI: 10.4251/wjgo.v2.i8.311] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
434 Kumar J, Bhargava M, Aggarwal S. Bevacizumab-induced reversible thrombocytopenia in a patient with adenocarcinoma of colon: rare adverse effect of bevacizumab. Case Rep Oncol Med 2012;2012:695430. [PMID: 23094167 DOI: 10.1155/2012/695430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
435 Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, Hata T, Denda T, Morita Y, Inukai M, Kunieda K, Nagata N, Kurachi K, Ina K, Ooshiro M, Shimoyama T, Baba H, Oba K, Sakamoto J, Mishima H. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol 2015;26:1427-33. [PMID: 25908603 DOI: 10.1093/annonc/mdv197] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
436 Rice C, Huang LE. From antiangiogenesis to hypoxia: current research and future directions. Cancer Manag Res 2010;3:9-16. [PMID: 21407995 DOI: 10.2147/CMR.S14812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
437 García-Alfonso P, Ferrer A, Gil S, Dueñas R, Pérez MT, Molina R, Capdevila J, Safont MJ, Castañón C, Cano JM, Lara R. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. Target Oncol 2015;10:453-65. [PMID: 25752908 DOI: 10.1007/s11523-015-0362-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
438 Meshcheryakova A, Tamandl D, Bajna E, Stift J, Mittlboeck M, Svoboda M, Heiden D, Stremitzer S, Jensen-Jarolim E, Grünberger T, Bergmann M, Mechtcheriakova D. B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. PLoS One 2014;9:e99008. [PMID: 24905750 DOI: 10.1371/journal.pone.0099008] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
439 Nam SO, Yotsumoto F, Miyata K, Fukagawa S, Yamada H, Kuroki M, Miyamoto S. Warburg effect regulated by amphiregulin in the development of colorectal cancer. Cancer Med. 2015;4:575-587. [PMID: 25644309 DOI: 10.1002/cam4.416] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
440 Xu Z, Zhu C, Chen C, Zong Y, Feng H, Liu D, Feng W, Zhao J, Lu A. CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway in colorectal cancer. Cell Death Dis 2018;9:974. [PMID: 30250188 DOI: 10.1038/s41419-018-1010-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 9.3] [Reference Citation Analysis]
441 Rossi L, Vakiarou F, Zoratto F, Bianchi L, Papa A, Basso E, Verrico M, Lo Russo G, Evangelista S, Rinaldi G, Perrone-Congedi F, Spinelli GP, Stati V, Caruso D, Prete A, Tomao S. Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). Cancer Manag Res. 2013;5:377-385. [PMID: 24399885 DOI: 10.2147/cmar.s47986] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
442 Choi M, Kollepara SL, Heilbrun LK, Smith D, Shields AF, Philip PA. PET scans as a predictive marker of survival in advanced colorectal cancer. Clin Colorectal Cancer 2015;14:35-40. [PMID: 25481195 DOI: 10.1016/j.clcc.2014.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
443 Kim ST, Hong YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Lee JW, Jo SJ, Park YS. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. BMC Cancer 2014;14:883. [PMID: 25424120 DOI: 10.1186/1471-2407-14-883] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
444 Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 2011;18:18-25. [PMID: 21331278 DOI: 10.3747/co.v18i1.708] [Cited by in Crossref: 188] [Cited by in F6Publishing: 183] [Article Influence: 17.1] [Reference Citation Analysis]
445 Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford) 2013;15:106-15. [PMID: 23297721 DOI: 10.1111/j.1477-2574.2012.00558.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
446 Bellio H, Bertaut A, Hervieu A, Zanetta S, Hennequin A, Vincent J, Palmier R, Bengrine-Lefevre L, Ghiringhelli F, Fumet JD. Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:5472. [PMID: 34771635 DOI: 10.3390/cancers13215472] [Reference Citation Analysis]
447 Worni M, Mantyh CR, Akushevich I, Pietrobon R, Clary BM. Is there a role for simultaneous hepatic and colorectal resections? A contemporary view from NSQIP. J Gastrointest Surg 2012;16:2074-85. [PMID: 22972010 DOI: 10.1007/s11605-012-1990-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
448 Newman NB, Moss RA, Maloney-Patel N, Donohue K, Brown TV, Nissenblatt MJ, Lu SE, Jabbour SK. Bone marrow tolerance during postoperative chemotherapy in colorectal carcinomas. J Gastrointest Oncol 2017;8:547-55. [PMID: 28736641 DOI: 10.21037/jgo.2017.01.19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
449 Stein A, Kretzschmar A, Behringer D, Wolff T, Zimber J, Hegewisch-Becker S, Kettner E, Pflüger KH, Kirsch A, Arnold D. Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial. BMC Cancer 2013;13:454. [PMID: 24090011 DOI: 10.1186/1471-2407-13-454] [Reference Citation Analysis]
450 Loree JM, Kopetz S. Recent developments in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol 2017;9:551-64. [PMID: 28794806 DOI: 10.1177/1758834017714997] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 10.8] [Reference Citation Analysis]
451 Fuloria J. Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer. Onco Targets Ther 2012;5:133-42. [PMID: 22930641 DOI: 10.2147/OTT.S31412] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
452 Kim Y, Kim TW, Han SW, Ahn JB, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK. A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Cancer Res Treat 2019;51:1128-34. [PMID: 30477287 DOI: 10.4143/crt.2018.379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
453 Ravoori MK, Nishimura M, Singh SP, Lu C, Han L, Hobbs BP, Pradeep S, Choi HJ, Bankson JA, Sood AK, Kundra V. Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. PLoS One 2015;10:e0131095. [PMID: 26098849 DOI: 10.1371/journal.pone.0131095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
454 Iwasa S, Okita N, Kuchiba A, Ogawa G, Kawasaki M, Nakamura K, Shoji H, Honma Y, Takashima A, Kato K, Hamaguchi T, Boku N, Yamada Y. Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503). ESMO Open 2020;5:e000776. [PMID: 32817132 DOI: 10.1136/esmoopen-2020-000776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
455 Jayson GC, Hicklin DJ, Ellis LM. Antiangiogenic therapy--evolving view based on clinical trial results. Nat Rev Clin Oncol 2012;9:297-303. [PMID: 22330688 DOI: 10.1038/nrclinonc.2012.8] [Cited by in Crossref: 105] [Cited by in F6Publishing: 90] [Article Influence: 10.5] [Reference Citation Analysis]
456 Zhang SD, Leung KL, McCrudden CM, Kwok HF. The Prognostic Significance of Combining VEGFA, FLT1 and KDR mRNA Expressions in Brain Tumors. J Cancer 2015;6:812-8. [PMID: 26284131 DOI: 10.7150/jca.11975] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
457 Paluri R, Madan A, Li P, Jones B, Saleh M, Jerome M, Miley D, Keef J, Robert F. Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2019;83:551-9. [PMID: 30603797 DOI: 10.1007/s00280-018-3761-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
458 Miyamoto Y, Suyama K, Baba H. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int J Mol Sci 2017;18:E752. [PMID: 28368335 DOI: 10.3390/ijms18040752] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
459 Marín-Pozo JF, Duarte-Pérez JM, Sánchez-Rovira P. Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience. Medicine (Baltimore) 2016;95:e3623. [PMID: 27175672 DOI: 10.1097/MD.0000000000003623] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
460 Yokokawa T, Kawakami K, Mae Y, Sugita K, Watanabe H, Suzuki K, Suenaga M, Mizunuma N, Yamaguchi T, Hama T. Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy. Ann Pharmacother 2015;49:1120-4. [PMID: 26160973 DOI: 10.1177/1060028015594451] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
461 Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91:1071-1121. [PMID: 21742796 DOI: 10.1152/physrev.00038.2010] [Cited by in Crossref: 887] [Cited by in F6Publishing: 851] [Article Influence: 80.6] [Reference Citation Analysis]
462 Dominietto M, Dobosz M, Bürgi S, Renner A, Zahlmann G, Scheuer W, Rudin M. Quantification of antiangiogenic treatment effects on tissue heterogeneity in glioma tumour xenograft model using a combination of DCE-MRI and 3D-ultramicroscopy. Eur Radiol 2017;27:2894-902. [PMID: 27830379 DOI: 10.1007/s00330-016-4629-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
463 Doi T, Boku N, Kato K, Komatsu Y, Yamaguchi K, Muro K, Hamamoto Y, Sato A, Koizumi W, Mizunuma N, Takiuchi H. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 2010;40:913-20. [PMID: 20462981 DOI: 10.1093/jjco/hyq069] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
464 Capalbo C, Belardinilli F, Raimondo D, Milanetti E, Malapelle U, Pisapia P, Magri V, Prete A, Pecorari S, Colella M, Coppa A, Bonfiglio C, Nicolussi A, Valentini V, Tessitore A, Cardinali B, Petroni M, Infante P, Santoni M, Filetti M, Colicchia V, Paci P, Mezi S, Longo F, Cortesi E, Marchetti P, Troncone G, Bellavia D, Canettieri G, Giannini G. A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. Cancers (Basel). 2019;11. [PMID: 30691222 DOI: 10.3390/cancers11020147] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
465 Patel SR, Karnad AB, Ketchum NS, Pollock BH, Sarantopoulos J, Weitman S, Mahalingam D. Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials. J Gastrointest Oncol 2014;5:99-103. [PMID: 24772337 DOI: 10.3978/j.issn.2078-6891.2014.002] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
466 Chen J, Zhang Y, Meng Z, Guo L, Yuan X, Zhang Y, Chai Y, Sessler JL, Meng Q, Li C. Supramolecular combination chemotherapy: a pH-responsive co-encapsulation drug delivery system. Chem Sci 2020;11:6275-82. [PMID: 32953023 DOI: 10.1039/d0sc01756f] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 6.5] [Reference Citation Analysis]
467 Wu Z, Guo HF, Xu H, Cheung NV. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers. Mol Cancer Ther 2018;17:2164-75. [PMID: 30082472 DOI: 10.1158/1535-7163.MCT-18-0026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
468 Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs 2014;74:1891-925. [PMID: 25315029 DOI: 10.1007/s40265-014-0302-9] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 15.1] [Reference Citation Analysis]
469 Zoratto F, Rossi L, Giordani E, Strudel M, Papa A, Tomao S. From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors. Tumour Biol 2014;35:8471-82. [PMID: 25062724 DOI: 10.1007/s13277-014-2367-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
470 Kieran MW, Chi S, Goldman S, Onar-Thomas A, Poussaint TY, Vajapeyam S, Fahey F, Wu S, Turner DC, Stewart CF, Moses M, Packer RJ, Jakacki R, Banerjee A, Boyett JM, Fouladi M, Kun L. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Childs Nerv Syst 2015;31:1433-45. [PMID: 26188774 DOI: 10.1007/s00381-015-2812-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
471 Matsuhashi N, Takahashi T, Matsui S, Tanahashi T, Imai H, Tanaka Y, Yamaguchi K, Yoshida K. A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. Int J Oncol 2018;52:1391-400. [PMID: 29568913 DOI: 10.3892/ijo.2018.4322] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
472 Teo M, Swan NC, McDermott RS. Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab. Nat Rev Urol 2011;8:282-5. [PMID: 21487385 DOI: 10.1038/nrurol.2011.48] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
473 Shankaran V, Mummy D, Koepl L, Bansal A, Mirick DK, Yu E, Morlock R, Ogale S, Ramsey SD. Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer. Oncologist 2014;19:892-9. [PMID: 25085899 DOI: 10.1634/theoncologist.2013-0209] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
474 Kim CW, Baek JH, Choi GS, Yu CS, Kang SB, Park WC, Lee BH, Kim HR, Oh JH, Kim JH, Jeong SY, Ahn JB, Baik SH. The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: Study protocol for a randomized controlled trial. Trials 2016;17:34. [PMID: 26782254 DOI: 10.1186/s13063-016-1164-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
475 Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 2013;18:273-80. [PMID: 23485622 DOI: 10.1634/theoncologist.2012-0339] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 8.2] [Reference Citation Analysis]
476 Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 2009;14:4517-45. [PMID: 19924084 DOI: 10.3390/molecules14114517] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 5.2] [Reference Citation Analysis]
477 Amadori M, Barone D, Scarpi E, Oboldi D, Amadori E, Bandi G, Rossi A, Ferroni F, Ragazzini A, Casadei Gardini A, Frassineti GL, Gavelli G, Passardi A. Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer. Eur Radiol 2018;28:2969-78. [PMID: 29417252 DOI: 10.1007/s00330-017-5254-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
478 Hofheinz RD, Ronellenfitsch U, Kubicka S, Falcone A, Burkholder I, Hacker UT. Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials. Gastroenterol Res Pract 2016;2016:9189483. [PMID: 27656206 DOI: 10.1155/2016/9189483] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
479 Sunakawa Y, Schirripa M, Lenz HJ. Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. Crit Rev Oncol Hematol 2016;100:117-26. [PMID: 26850575 DOI: 10.1016/j.critrevonc.2016.01.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
480 Shu C, Sun P, Xie H, Huang W, Qi J, Ma Y. Virus-Like Particles Presenting the FGF-2 Protein or Identified Antigenic Peptides Promoted Antitumor Immune Responses in Mice. Int J Nanomedicine 2020;15:1983-96. [PMID: 32308382 DOI: 10.2147/IJN.S237182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
481 Boyle JM, Cowling TE, Kuryba A, Fearnhead NS, van der Meulen J, Braun MS, Walker K, Aggarwal A. Development and validation of a coding framework to identify severe acute toxicity from systemic anti-cancer therapy using hospital administrative data. Cancer Epidemiology 2022;77:102096. [DOI: 10.1016/j.canep.2022.102096] [Reference Citation Analysis]
482 Zhou YW, Long YX, Chen Y, Liu JY, Pu D, Huang JY, Bi F, Li Q, Gou HF, Qiu M. First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component. Cancer Med 2021;10:3388-402. [PMID: 33939281 DOI: 10.1002/cam4.3876] [Reference Citation Analysis]
483 Sartori S, Tombesi P, Di Vece F. Thermal ablation in colorectal liver metastases: Lack of evidence or lack of capability to prove the evidence? World J Gastroenterol. 2016;22:3511-3515. [PMID: 27053843 DOI: 10.3748/wjg.v22.il3.3511] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
484 Paiva TF Jr, de Jesus VH, Marques RA, da Costa AA, de Macedo MP, Peresi PM, Damascena A, Rossi BM, Begnami MD, de Lima VC. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. BMC Cancer 2015;15:643. [PMID: 26394830 DOI: 10.1186/s12885-015-1648-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
485 Pamecha V, Levene A, Grillo F, Woodward N, Dhillon A, Davidson BR. Effect of portal vein embolisation on the growth rate of colorectal liver metastases. Br J Cancer. 2009;100:617-622. [PMID: 19209170 DOI: 10.1038/sj.bjc.6604872] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 6.5] [Reference Citation Analysis]
486 Jiang C, Huang YH, Lu JB, Yang YZ, Rao HL, Zhang B, He WZ, Xia LP. Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer. Cancer Manag Res 2018;10:3589-97. [PMID: 30271207 DOI: 10.2147/CMAR.S172261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
487 Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med 2012;2:a006486. [PMID: 22393532 DOI: 10.1101/cshperspect.a006486] [Cited by in Crossref: 200] [Cited by in F6Publishing: 187] [Article Influence: 22.2] [Reference Citation Analysis]
488 Devaud N, Kanji ZS, Dhani N, Grant RC, Shoushtari H, Serrano PE, Nanji S, Greig PD, McGilvray I, Moulton CA, Wei A, Gallinger S, Cleary SP. Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases. HPB (Oxford) 2014;16:475-80. [PMID: 23927606 DOI: 10.1111/hpb.12159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
489 Pereira DM, Simões AE, Gomes SE, Castro RE, Carvalho T, Rodrigues CM, Borralho PM. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism. Oncotarget 2016;7:34322-40. [PMID: 27144434 DOI: 10.18632/oncotarget.9107] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
490 Petracci E, Scarpi E, Passardi A, Biggeri A, Milandri C, Vecchia S, Gelsomino F, Tassinari D, Tamberi S, Bernardini I, Accettura C, Frassineti GL, Amadori D, Nanni O. Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial. Ther Adv Med Oncol 2020;12:1758835920937427. [PMID: 32754229 DOI: 10.1177/1758835920937427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
491 Nakayama G, Tanaka C, Kodera Y. Current Options for the Diagnosis, Staging and Therapeutic Management of Colorectal Cancer. Gastrointest Tumors 2013;1:25-32. [PMID: 26674429 DOI: 10.1159/000354995] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
492 Kato J, Futamura M, Kanematsu M, Gaowa S, Mori R, Tanahashi T, Matsuhashi N, Yoshida K. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status. Int J Cancer 2016;138:1516-27. [PMID: 26437179 DOI: 10.1002/ijc.29881] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
493 Saerens M, De Jaeghere EA, Kanervo H, Vandemaele N, Denys H, Naert E. Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:4603. [PMID: 34572830 DOI: 10.3390/cancers13184603] [Reference Citation Analysis]
494 Hachiya H, Ishizuka M, Takagi K, Iwasaki Y, Shibuya N, Nishi Y, Aoki T, Kubota K. Clinical significance of the globulin-to-albumin ratio for prediction of postoperative survival in patients with colorectal cancer. Ann Gastroenterol Surg 2018;2:434-41. [PMID: 30460347 DOI: 10.1002/ags3.12201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
495 Aggarwal A, Fojo T, Chamberlain C, Davis C, Sullivan R. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund. Ann Oncol 2017;28:1738-50. [PMID: 28453615 DOI: 10.1093/annonc/mdx110] [Cited by in Crossref: 63] [Cited by in F6Publishing: 45] [Article Influence: 15.8] [Reference Citation Analysis]
496 Schmiegel W, Pox C, Arnold D, Porschen R, Rödel C, Reinacher-Schick A; Association of the Scientific Medical Societies in Germany., German Cancer Aid., German Cancer Society., German Society for Digestive and Metabolic Diseases., German Society for General and Visceral Surgery., German Society for Hematology and Oncology., German Society for Pathology., German Society for Radiooncology., German Roentgen Society., German Joint Society for Clinical Chemistry and Laboratory Medicine., German Society for Coloproctology., Association of Stoma Patients and Persons with Intestinal Cancer., German Crohn's Disease and Ulcerative Colitis Association., German Society for Internal Medicine. Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases. Dtsch Arztebl Int 2009;106:843-8. [PMID: 20062582 DOI: 10.3238/arztebl.2009.0843] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.2] [Reference Citation Analysis]
497 Goldstein DA, Zeichner SB, Bartnik CM, Neustadter E, Flowers CR. Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. Clin Colorectal Cancer 2016;15:1-6. [PMID: 26541320 DOI: 10.1016/j.clcc.2015.10.002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
498 Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Kaur H, Charnsangavej C, Loyer EM. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302:2338-2344. [PMID: 19952320 DOI: 10.1001/jama.2009.1755] [Cited by in Crossref: 352] [Cited by in F6Publishing: 316] [Article Influence: 27.1] [Reference Citation Analysis]
499 Cascales-Campos PA, López-López V, Torres-Melero J, Arjona A, Muñoz-Casares FC, Barrios P, Morales R, Pereira F, Bretcha-Boix P, González-Bayón L, González-Moreno S, Gil J. Survival outcomes in patients aged 75 years and over with peritoneal colorectal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): multicenter study of the Spanish Group of Peritoneal Cancer Surgery (GECOP). Clin Transl Oncol 2020;22:130-6. [PMID: 31049819 DOI: 10.1007/s12094-019-02124-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
500 Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 2009;9:347. [PMID: 19785749 DOI: 10.1186/1471-2407-9-347] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
501 Zhou H, Wang Y, Lin Y, Cai W, Li X, He X. Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study. Front Oncol 2021;11:774445. [PMID: 34900725 DOI: 10.3389/fonc.2021.774445] [Reference Citation Analysis]
502 Rabe E, Cioni D, Baglietto L, Fornili M, Gabelloni M, Neri E. Can the computed tomography texture analysis of colorectal liver metastases predict the response to first-line cytotoxic chemotherapy? World J Hepatol 2022; 14(1): 244-259 [DOI: 10.4254/wjh.v14.i1.244] [Reference Citation Analysis]
503 Ranieri G, Laface C, Laforgia M, De Summa S, Porcelli M, Macina F, Ammendola M, Molinari P, Lauletta G, Di Palo A, Rubini G, Ferrari C, Gadaleta CD. Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study. Front Oncol 2020;10:590707. [PMID: 33224885 DOI: 10.3389/fonc.2020.590707] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
504 Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins JN, Seay TE, Fehrenbacher L, O'Reilly S, Chu L, Azar CA, Wolmark N. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009;27:3385-90. [PMID: 19414665 DOI: 10.1200/JCO.2009.21.9220] [Cited by in Crossref: 189] [Cited by in F6Publishing: 87] [Article Influence: 14.5] [Reference Citation Analysis]
505 Matsui T, Kitamura T, Ozawa H, Matsuguma H, Kotake K. Analysis of treatment that includes both hepatic and pulmonary resections for colorectal metastases. Surg Today 2014;44:702-11. [PMID: 24170275 DOI: 10.1007/s00595-013-0769-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
506 Matsumoto N, Kubota Y, Ishida H, Sekido M, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Ikusue T, Kobayashi K, Hisamatsu A, Toshima H, Shimada K, Fujita KI. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients. Cancer Chemother Pharmacol 2020;85:1119-28. [PMID: 32458030 DOI: 10.1007/s00280-020-04087-z] [Reference Citation Analysis]
507 Kim M, Lee C, Payne R, Yue BY, Chang JH, Ying H. Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review. Surv Ophthalmol 2015;60:524-35. [PMID: 25980779 DOI: 10.1016/j.survophthal.2015.04.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
508 Aguado C, García-Paredes B, Sotelo MJ, Sastre J, Díaz-Rubio E. Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? World J Gastroenterol 2014; 20(20): 6092-6101 [PMID: 24876731 DOI: 10.3748/wjg.v20.i20.6092] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
509 Chibaudel B, Tournigand C, Bonnetain F, Richa H, Benetkiewicz M, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. Ther Adv Med Oncol 2015;7:153-69. [PMID: 26673925 DOI: 10.1177/1758834015572343] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
510 Hultman B, Mahteme H, Sundbom M, Ljungman M, Larsson R, Nygren P. Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy. J Exp Clin Cancer Res. 2014;33:110. [PMID: 25528067 DOI: 10.1186/s13046-014-0110-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
511 Shubert CR, Habermann EB, Bergquist JR, Thiels CA, Thomsen KM, Kremers WK, Kendrick ML, Cima RR, Nagorney DM. A NSQIP Review of Major Morbidity and Mortality of Synchronous Liver Resection for Colorectal Metastasis Stratified by Extent of Liver Resection and Type of Colorectal Resection. J Gastrointest Surg. 2015;19:1982-1994. [PMID: 26239515 DOI: 10.1007/s11605-015-2895-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
512 Chu E, Haller D, Cartwright T, Twelves C, Cassidy J, Sun W, Saif MW, McKenna E, Lee S, Schmoll HJ. Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial. Br J Cancer 2014;110:1438-45. [PMID: 24548866 DOI: 10.1038/bjc.2014.74] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
513 Riechelmann R, Grothey A. Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Ther Adv Med Oncol 2017;9:106-26. [PMID: 28203302 DOI: 10.1177/1758834016676703] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
514 Chen J, Wang J, Ni T, He H, Zheng Q. Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma. Medicine (Baltimore) 2020;99:e19908. [PMID: 32569154 DOI: 10.1097/MD.0000000000019908] [Reference Citation Analysis]
515 Murono K, Nozawa H, Nagata H, Ishimaru K, Sonoda H, Emoto S, Kaneko M, Sasaki K, Otani K, Kawai K, Muro K, Ishihara S. Efficacy of intraperitoneally administered paclitaxel for colorectal cancer with peritoneal metastases. Int J Colorectal Dis 2020;35:1945-9. [PMID: 32495229 DOI: 10.1007/s00384-020-03649-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
516 Wang H, Ma B, Gao P, Song Y, Xu Q, Hu Y, Zhang C, Wang Z. Efficacy and safety of anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy for metastatic colorectal cancer in first-line and second-line therapies: a meta-analysis. Onco Targets Ther 2016;9:5405-16. [PMID: 27621654 DOI: 10.2147/OTT.S111240] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
517 Leighl NB, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer. 2011;104:413-418. [PMID: 21245868 DOI: 10.1038/sj.bjc.6606074] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
518 Yao Y, Liu Z, Zhang H, Li J, Peng Z, Yu J, Cao B, Shen L. Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis. Front Pharmacol 2021;12:754858. [PMID: 34867369 DOI: 10.3389/fphar.2021.754858] [Reference Citation Analysis]
519 Shin SJ, Hwang JW, Ahn JB, Rha SY, Roh JK, Chung HC. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. Invest New Drugs. 2013;31:1-13. [PMID: 22539090 DOI: 10.1007/s10637-012-9817-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
520 Schiffer M, Zukovic L, Hall S, Merl MY. Assessment of extended urine protein monitoring frequency in patients receiving bevacizumab. J Oncol Pharm Pract 2021;27:902-6. [PMID: 32715917 DOI: 10.1177/1078155220943959] [Reference Citation Analysis]
521 Ciombor KK, Goldberg RM. Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer. Hepat Oncol 2014;1:331-45. [PMID: 30190967 DOI: 10.2217/hep.14.13] [Reference Citation Analysis]
522 Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23:2619-2626. [PMID: 22431703 DOI: 10.1093/annonc/mds053] [Cited by in Crossref: 241] [Cited by in F6Publishing: 207] [Article Influence: 24.1] [Reference Citation Analysis]
523 Rahbari NN, Lordick F, Fink C, Bork U, Stange A, Jäger D, Luntz SP, Englert S, Rossion I, Koch M. Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS--a randomised controlled multicentre trial (ISRCTN30964555). BMC Cancer. 2012;12:142. [PMID: 22480173 DOI: 10.1186/1471-2407-12-142] [Cited by in Crossref: 81] [Cited by in F6Publishing: 67] [Article Influence: 8.1] [Reference Citation Analysis]
524 Kamiyoshihara M, Igai H, Kawatani N, Ibe T, Tomizawa N, Obayashi K, Shimizu K, Takeyoshi I. Lung metastasectomy for postoperative colorectal cancer in patients with a history of hepatic metastasis. Gen Thorac Cardiovasc Surg. 2014;62:314-320. [PMID: 24505023 DOI: 10.1007/s11748-014-0376-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
525 Bulajic P, Bidzic N, Djordjevic V, Ceranic Μ, Βasaric D, Pesic V, Djordjevic-Pesic J. Impact of Genetics on Neoadjuvant Therapy with Complete Pathological Response in Metastatic Colorectal Cancer: Case Report and Review of the Literature. Balkan J Med Genet 2019;22:75-80. [PMID: 31523624 DOI: 10.2478/bjmg-2019-0004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
526 Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow H, Duckworth A, Heister P, Praseedom R, Jah A, Balakrishnan A, Harper S, Liau S, Kosmoliaptsis V, Huguet E. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol 2020; 11(10): 761-808 [PMID: 33200074 DOI: 10.5306/wjco.v11.i10.761] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
527 Suzuki N, Nakagawa F, Takechi T. Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer. Oncol Lett 2017;14:639-46. [PMID: 28693216 DOI: 10.3892/ol.2017.6258] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
528 Peungjesada S, Chuang HH, Prasad SR, Choi H, Loyer EM, Bronstein Y. Evaluation of cancer treatment in the abdomen: Trends and advances. World J Radiol 2013; 5(3): 126-142 [PMID: 23671749 DOI: 10.4329/wjr.v5.i3.126] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
529 Creutzfeldt A, Suling A, Oechsle K, Mehnert A, Atanackovic D, Kripp M, Arnold D, Stein A, Quidde J. Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study. BMC Palliat Care 2016;15:25. [PMID: 26928745 DOI: 10.1186/s12904-016-0101-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
530 Sinicrope FA. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol. 2010;7:174-177. [PMID: 20190798 DOI: 10.1038/nrclinonc.2009.235] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
531 Pedrosa L, Esposito F, Thomson TM, Maurel J. The Tumor Microenvironment in Colorectal Cancer Therapy. Cancers (Basel) 2019;11:E1172. [PMID: 31416205 DOI: 10.3390/cancers11081172] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
532 Garcia-Alfonso P, Chaves M, Muñoz A, Salud A, García-Gonzalez M, Grávalos C, Massuti B, González-Flores E, Queralt B, López-Ladrón A, Losa F, Gómez MJ, Oltra A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC Cancer 2015;15:327. [PMID: 25925749 DOI: 10.1186/s12885-015-1293-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
533 Sasaki A, Harano K, Kogawa T, Matsubara N, Naito Y, Hosono A, Mukai H, Yoshino T, Mukohara T. Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer. Case Rep Oncol Med 2020;2020:7231358. [PMID: 32612862 DOI: 10.1155/2020/7231358] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
534 Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Di Desidero T, Canu B, Schirripa M, Frumento P. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer. 2011;104:1262-1269. [PMID: 21407216 DOI: 10.1038/bjc.2011.85] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 6.6] [Reference Citation Analysis]
535 Fu AZ, Zhao Z, Gao S, Barber B, Liu GG. Comorbid Conditions in Patients With Metastatic Colorectal Cancer. World J Oncol 2011;2:225-31. [PMID: 29147252 DOI: 10.4021/wjon370e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
536 Wang TF, Lockhart AC. Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol 2012;6:19-30. [PMID: 22253552 DOI: 10.4137/CMO.S7432] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
537 Hosokawa A, Yamazaki K, Matsuda C, Ueda S, Kusaba H, Okamura S, Tsuda M, Tamura T, Shinozaki K, Tsushima T, Tsuda T, Shirakawa T, Yamashita H, Morita S, Hironaka S, Muro K. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study. Medicine (Baltimore) 2020;99:e22060. [PMID: 32899071 DOI: 10.1097/MD.0000000000022060] [Reference Citation Analysis]
538 Macaulay R, Ahuja A, Ademisoye E, Juarez-Garcia A, Shaw JW. Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective. Clinicoecon Outcomes Res 2019;11:199-219. [PMID: 30936729 DOI: 10.2147/CEOR.S177343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
539 Fu AZ, Tsai HT, Marshall JL, Freedman AN, Potosky AL. Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapy. J Oncol Pharm Pract 2014;20:332-40. [PMID: 24122849 DOI: 10.1177/1078155213507010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
540 Takahashi N, Iwasa S, Taniguchi H, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita N, Kato K, Hamaguchi T, Shimada Y, Yamada Y. Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies. Br J Cancer 2016;114:1003-11. [PMID: 27002940 DOI: 10.1038/bjc.2016.74] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
541 Moriwaki T, Bando H, Takashima A, Yamazaki K, Esaki T, Yamashita K, Fukunaga M, Miyake Y, Katsumata K, Kato S, Satoh T, Ozeki M, Baba E, Yoshida S, Boku N, Hyodo I. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Med Oncol 2012;29:2842-8. [PMID: 22209842 DOI: 10.1007/s12032-011-0151-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
542 Hoh CK, Burris HA 3rd, Bendell JC, Tarazi J, Rosbrook B, Kim S, Infante JR, Reid TR. Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours. Br J Cancer 2014;110:875-81. [PMID: 24423921 DOI: 10.1038/bjc.2013.806] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
543 Fetterly GJ, Aras U, Lal D, Murphy M, Meholick PD, Wang ES. Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemia. AAPS J 2013;15:662-73. [PMID: 23550025 DOI: 10.1208/s12248-013-9480-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
544 Chua TC, Bester L, Saxena A, Morris DL. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol 2011;137:865-73. [PMID: 20859640 DOI: 10.1007/s00432-010-0948-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
545 Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res 2019;38:156. [PMID: 30975211 DOI: 10.1186/s13046-019-1094-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 19.3] [Reference Citation Analysis]
546 Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D. Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clin Pharmacokinet 2016;55:1381-94. [PMID: 27312193 DOI: 10.1007/s40262-016-0406-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
547 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207-239. [PMID: 25782566 DOI: 10.1007/s10147-015-0801-z] [Cited by in Crossref: 379] [Cited by in F6Publishing: 363] [Article Influence: 54.1] [Reference Citation Analysis]
548 Kim CW, Chon HJ, Kim C. Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer. Cancers (Basel) 2021;13:4906. [PMID: 34638390 DOI: 10.3390/cancers13194906] [Reference Citation Analysis]
549 Lee J, Shin SJ, Chung IJ, Kim TW, Chun HG, Shin DB, Kim YH, Song HS, Han SW, Kim JG, Kim SY, Choi YJ, Chung HC. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Invest New Drugs 2014;32:561-8. [PMID: 24573743 DOI: 10.1007/s10637-014-0075-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
550 Kim SY, Lee JS, Kang J, Morita S, Park YS, Sakamoto J, Muro K, Xu RH, Kim TW. Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT). Oncologist 2021;26:e954-62. [PMID: 33644953 DOI: 10.1002/onco.13735] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
551 Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013;8:e77117. [PMID: 24143206 DOI: 10.1371/journal.pone.0077117] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 7.4] [Reference Citation Analysis]
552 Hohla F, Winder T, Greil R, Rick FG, Block NL, Schally AV. Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. World J Gastroenterol 2014; 20(20): 6102-6112 [PMID: 24876732 DOI: 10.3748/wjg.v20.i20.6102] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
553 Tomizawa K, Ando K, Shimada H, Kaminuma T, Murata K, Oike T, Ohno T. Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose-volume analysis. Clin Case Rep 2021;9:2099-104. [PMID: 33936646 DOI: 10.1002/ccr3.3955] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
554 Zhu X, Tian X, Yu C, Hong J, Fang J, Chen H. Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials. Medicine (Baltimore) 2016;95:e4232. [PMID: 27559943 DOI: 10.1097/MD.0000000000004232] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
555 Peeters M, Strickland AH, Lichinitser M, Suresh AV, Manikhas G, Shapiro J, Rogowski W, Huang X, Wu B, Warner D, Jain R, Tebbutt NC. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 2013;108:503-11. [PMID: 23361051 DOI: 10.1038/bjc.2012.594] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
556 Levin PA, Dowell JE. Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date. Onco Targets Ther 2017;10:2057-66. [PMID: 28435296 DOI: 10.2147/OTT.S113598] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
557 Kim SY, Lee DH, Song X, Bartlett DL, Kwon YT, Lee YJ. Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells. Apoptosis. 2014;19:1603-1615. [PMID: 25156145 DOI: 10.1007/s10495-014-1028-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
558 Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol 2014;32:1620-9. [PMID: 24711558 DOI: 10.1200/JCO.2013.53.0204] [Cited by in Crossref: 39] [Cited by in F6Publishing: 13] [Article Influence: 4.9] [Reference Citation Analysis]
559 Meijerink MR, Puijk RS, van Tilborg AAJM, Henningsen KH, Fernandez LG, Neyt M, Heymans J, Frankema JS, de Jong KP, Richel DJ, Prevoo W, Vlayen J. Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. Cardiovasc Intervent Radiol. 2018;41:1189-1204. [PMID: 29666906 DOI: 10.1007/s00270-018-1959-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 15.8] [Reference Citation Analysis]
560 Snyder A, Kemeny N, Shamseddine A, Al-Olayan A, El-Merhi F, Kelsen DP, Jamali F, Sidani M, Mukherji D, El-Naghy M, O'Reilly EM, Saltz LB, Abou-Alfa GK. Liver-directed conversion therapy in metastatic colon cancer. J Gastrointest Oncol 2015;6:322-8. [PMID: 26029460 DOI: 10.3978/j.issn.2078-6891.2015.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
561 Bogach J, Levine O, Parpia S, Valencia M, Ruo L, Serrano P. Does the Addition of Biologic Agents to Chemotherapy in Patients with Unresectable Colorectal Cancer Metastases Result in a Higher Proportion of Patients Undergoing Resection? A Systematic Review and Meta-analysis. J Gastrointest Surg 2018;22:523-8. [PMID: 29204907 DOI: 10.1007/s11605-017-3640-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
562 Huellner MW, Hennedige TP, Winterhalder R, Zander T, Venkatesh SK, Yong WP, Soo RA, Seifert B, Treumann TC, Strobel K, Veit-Haibach P. Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer. Cancer Imaging 2012;12:212-24. [PMID: 22750105 DOI: 10.1102/1470-7330.2012.0021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
563 Fujita KI, Kubota Y, Ishida H, Sasaki Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 2015; 21(43): 12234-12248 [PMID: 26604633 DOI: 10.3748/wjg.v21.i43.12234] [Cited by in CrossRef: 121] [Cited by in F6Publishing: 106] [Article Influence: 17.3] [Reference Citation Analysis]
564 Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S. Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther 2012;5:199-211. [PMID: 23055745 DOI: 10.2147/OTT.S30581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
565 Ikoma N, Raghav K, Chang G. An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surg Oncol Clin N Am. 2017;26:667-687. [PMID: 28923224 DOI: 10.1016/j.soc.2017.05.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
566 Nogué M, Salud A, Vicente P, Arriví A, Roca JM, Losa F, Ponce J, Safont MJ, Guasch I, Moreno I. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011;16:614-620. [PMID: 21467148 DOI: 10.1634/theoncologist.2010-0285] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 9.1] [Reference Citation Analysis]
567 Chan DL, Pavlakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Segelov E. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS One. 2015;10:e0135599. [PMID: 26275292 DOI: 10.1371/journal.pone.0135599] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
568 Aprile G, Fontanella C, Lutrino ES, Ferrari L, Casagrande M, Cardellino GG, Rosati G, Fasola G. Angiogenic inhibitors for older patients with advanced colorectal cancer: Does the age hold the stage? World J Gastroenterol 2013; 19(14): 2131-2140 [PMID: 23847406 DOI: 10.3748/wjg.v19.i14.2131] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
569 Wang F, Dai G, Deng Y, Tang Y, Wang W, Niu Z, Bi F, Zhu L, Guo Z, Yan J, Hu B, Tao M, Yang S, Zhang S, Wen L, Xu R. Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial. Chin J Cancer Res 2021;33:490-9. [PMID: 34584374 DOI: 10.21147/j.issn.1000-9604.2021.04.06] [Reference Citation Analysis]
570 Clarke S, Burge M, Cordwell C, Gibbs P, Reece W, Tebbutt N. An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]. BMC Cancer 2013;13:120. [PMID: 23497305 DOI: 10.1186/1471-2407-13-120] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
571 Shady W, Sotirchos VS, Do RK, Pandit-Taskar N, Carrasquillo JA, Gonen M, Sofocleous CT. Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres. AJR Am J Roentgenol 2016;207:661-70. [PMID: 27384594 DOI: 10.2214/AJR.15.15202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
572 Grothey A. Medical treatment of advanced colorectal cancer in 2009. Ther Adv Med Oncol 2009;1:55-68. [PMID: 21789113 DOI: 10.1177/1758834009343302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
573 Prager G, Argilés G. Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer. ESMO Open 2017;2:e000205. [PMID: 29303156 DOI: 10.1136/esmoopen-2017-000205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
574 Hu H, Liu X, Cai W, Wu D, Xu J, Yuan Y. A Retrospective Exploration of Targeted Maintenance Therapy in Advanced Colorectal Cancer: Based on the Background of Chinese Patient Assistance Program. Front Oncol 2020;10:522. [PMID: 32391263 DOI: 10.3389/fonc.2020.00522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
575 Betof AS, Lascola CD, Weitzel D, Landon C, Scarbrough PM, Devi GR, Palmer G, Jones LW, Dewhirst MW. Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise. J Natl Cancer Inst 2015;107:djv040. [PMID: 25780062 DOI: 10.1093/jnci/djv040] [Cited by in Crossref: 111] [Cited by in F6Publishing: 104] [Article Influence: 15.9] [Reference Citation Analysis]
576 Lv C, Wu S, Zheng D, Wu Y, Yao D, Yu X. The Efficacy of Additional Bevacizumab to Cytotoxic Chemotherapy Regimens for the Treatment of Colorectal Cancer: An Updated Meta-Analysis for Randomized Trials. Cancer Biother Radiopharm. 2013;28:501-509. [PMID: 23768086 DOI: 10.1089/cbr.2012.1458] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
577 Liu Z, Chen Y, Su Y, Hu X, Peng X. Nasopharyngeal Carcinoma: Clinical Achievements and Considerations Among Treatment Options. Front Oncol 2021;11:635737. [PMID: 34912697 DOI: 10.3389/fonc.2021.635737] [Reference Citation Analysis]
578 Zhang Y, Rajput A, Jin N, Wang J. Mechanisms of Immunosuppression in Colorectal Cancer. Cancers (Basel) 2020;12:E3850. [PMID: 33419310 DOI: 10.3390/cancers12123850] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
579 Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, Yoshino T, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll HJ, Goldberg R, Hoff P, Hecht JR, Hurwitz H, Punt C, Diaz Rubio E, Koopman M, Cremolini C, Heinemann V, Tournigard C, Bokemeyer C, Fuchs C, Tebbutt N, Souglakos J, Doulliard JY, Kabbinavar F, Chibaudel B, de Gramont A, Shi Q, Grothey A, Adams R. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Ther Adv Med Oncol 2021;13:17588359211020547. [PMID: 34262614 DOI: 10.1177/17588359211020547] [Reference Citation Analysis]
580 Vera R, Gomez Dorronsoro M, Lopez-Ben S, Viudez A, Queralt B, Hernandez I, Ortiz-Duran MR, Zazpe C, Soriano J, Amat I, Herrera Cabezón J, Diaz E, Codina-Barreras A, Hernandez-Yagüe X, Quera A, Figueras J. Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab. Clin Transl Oncol 2014;16:739-45. [PMID: 24338508 DOI: 10.1007/s12094-013-1142-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
581 Sumransub N, Vantanasiri K, Prakash A, Lou E. Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success? Mol Ther Oncolytics 2021;22:1-12. [PMID: 34307839 DOI: 10.1016/j.omto.2021.05.001] [Reference Citation Analysis]
582 Jouinot A, Coriat R, Huillard O, Goldwasser F. Les biothérapies des cancers colorectaux métastatiques en 2014. La Presse Médicale 2014;43:1056-66. [DOI: 10.1016/j.lpm.2014.03.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
583 Vickers M, Samson B, Colwell B, Cripps C, Jalink D, El-Sayed S, Chen E, Porter G, Goel R, Villeneuve J, Sundaresan S, Asselah J, Biagi J, Jonker D, Dawson L, Letourneau R, Rother M, Maroun J, Thirlwell M, Hussein M, Tehfe M, Perrin N, Michaud N, Hammad N, Champion P, Rajan R, Burkes R, Barrette S, Welch S, Yarom N, Asmis T. Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease. Curr Oncol 2010;17:70-7. [PMID: 20651901 DOI: 10.3747/co.v17i3.610] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
584 Osterlund P, Peltonen R, Alanko T, Bono P, Isoniemi H. A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. Onco Targets Ther. 2014;7:1177-1184. [PMID: 25061319 DOI: 10.2147/ott.s63739] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
585 Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17:471-94. [PMID: 24482243 DOI: 10.1007/s10456-014-9420-y] [Cited by in Crossref: 415] [Cited by in F6Publishing: 389] [Article Influence: 51.9] [Reference Citation Analysis]
586 Park SH, Lee DH, Kim JL, Kim BR, Na YJ, Jo MJ, Jeong YA, Lee SY, Lee SI, Lee YY, Oh SC. Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells. Oncotarget 2016;7:59503-18. [PMID: 27517746 DOI: 10.18632/oncotarget.11147] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
587 Weickhardt AJ, Williams DS, Lee CK, Chionh F, Simes J, Murone C, Wilson K, Parry MM, Asadi K, Scott AM, Punt CJ, Nagtegaal ID, Price TJ, Mariadason JM, Tebbutt NC. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. Br J Cancer 2015;113:37-45. [PMID: 26125443 DOI: 10.1038/bjc.2015.209] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
588 Marmorino F, Salvatore L, Barbara C, Allegrini G, Antonuzzo L, Masi G, Loupakis F, Borelli B, Chiara S, Banzi MC, Miraglio E, Amoroso D, Dargenio F, Bonetti A, Martignetti A, Paris M, Tomcikova D, Boni L, Falcone A, Cremolini C. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. Br J Cancer 2017;116:318-23. [PMID: 28081548 DOI: 10.1038/bjc.2016.413] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
589 Eefsen RL, Van den Eynden GG, Høyer-Hansen G, Brodt P, Laerum OD, Vermeulen PB, Christensen IJ, Wettergren A, Federspiel B, Willemoe GL, Vainer B, Osterlind K, Illemann M. Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases. J Oncol 2012;2012:907971. [PMID: 22919385 DOI: 10.1155/2012/907971] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
590 Ulivi P, Marisi G, Passardi A. Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. Oncotarget 2016;7:46678-91. [PMID: 27081084 DOI: 10.18632/oncotarget.8712] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
591 Botrel TEA, Clark LGO, Paladini L, Clark OAC. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2016;16:677. [PMID: 27558497 DOI: 10.1186/s12885-016-2734-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
592 Saijo N. Present status and problems on molecular targeted therapy of cancer. Cancer Res Treat 2012;44:1-10. [PMID: 22500155 DOI: 10.4143/crt.2012.44.1.1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
593 Midgley RS, Yanagisawa Y, Kerr DJ. Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol 2009;6:108-20. [PMID: 19153564 DOI: 10.1038/ncpgasthep1337] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
594 Hornberger J, Degtiar I, Gutierrez H, Shewade A, Henner WD, Becker S, Varadhachary G, Raab S. Cost-effectiveness of gene-expression profiling for tumor-site origin. Value Health 2013;16:46-56. [PMID: 23337215 DOI: 10.1016/j.jval.2012.09.005] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
595 Naruse T, Goi T, Yamaguchi A. Prokineticin-1 induces normal lymphangiogenic activity and is involved in lymphangiogenesis and lymph node metastasis in colorectal cancer. Oncotarget 2021;12:1388-97. [PMID: 34262649 DOI: 10.18632/oncotarget.28016] [Reference Citation Analysis]
596 Zunder SM, van Pelt GW, Gelderblom HJ, Mancao C, Putter H, Tollenaar RA, Mesker WE. Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer. Br J Cancer 2018;119:164-9. [PMID: 29755119 DOI: 10.1038/s41416-018-0083-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
597 El Bali M, Bakkach J, Bennani Mechita M. Colorectal Cancer: From Genetic Landscape to Targeted Therapy. J Oncol 2021;2021:9918116. [PMID: 34326875 DOI: 10.1155/2021/9918116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
598 Hata A, Katakami N, Fujita S, Takatori K, Horai A, Kitajima N, Terashima K. Panitumumab rechallenge in chemorefractory patients with metastatic colorectal cancer. J Gastrointest Cancer 2013;44:456-9. [PMID: 23212286 DOI: 10.1007/s12029-012-9453-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
599 Rudek MA, Dasari A, Laheru D, He P, Jin R, Walker R, Taylor GE, Jimeno A, Donehower RC, Hidalgo M, Messersmith WA, Purcell WT. Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer. J Clin Pharmacol 2016;56:966-73. [PMID: 26632033 DOI: 10.1002/jcph.681] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
600 Gangadhar T, Schilsky RL. Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010;7:318-325. [PMID: 20440283 DOI: 10.1038/nrclinonc.2010.62] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
601 Kerscher AG, Chua TC, Gasser M, Maeder U, Kunzmann V, Isbert C, Germer CT, Pelz JO. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer. 2013;108:1432-1439. [PMID: 23511564 DOI: 10.1038/bjc.2013.82] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 7.3] [Reference Citation Analysis]
602 Mulder K, Koski S, Scarfe A, Chu Q, King K, Spratlin J. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget 2010;1:515-29. [PMID: 21317448 DOI: 10.18632/oncotarget.101006] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
603 Amin M, Desai M, Trinkaus K, Brown A, Wang-Gillam A, Tan B, Picus J, Sorscher S, Highkin M, Lears K, Lockhart AC. Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer. J Gastrointest Oncol 2019;10:412-20. [PMID: 31183190 DOI: 10.21037/jgo.2019.02.01] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
604 Geng ZH, Ye CX, Huang Y, Jiang HP, Ye YJ, Wang S, Zhou Y, Shen ZL, Qiu XY. Human colorectal cancer cells frequently express IgG and display unique Ig repertoire. World J Gastrointest Oncol 2019; 11(3): 195-207 [PMID: 30918593 DOI: 10.4251/wjgo.v11.i3.195] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
605 Chowdhury R, Ganeshan B, Irshad S, Lawler K, Eisenblätter M, Milewicz H, Rodriguez-Justo M, Miles K, Ellis P, Groves A, Punwani S, Ng T. The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis. Br J Radiol 2014;87:20140065. [PMID: 24597512 DOI: 10.1259/bjr.20140065] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
606 Fan F, Samuel S, Gaur P, Lu J, Dallas NA, Xia L, Bose D, Ramachandran V, Ellis LM. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer 2011;104:1270-7. [PMID: 21407219 DOI: 10.1038/bjc.2011.81] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 5.6] [Reference Citation Analysis]
607 Angelucci A, Delle Monache S, Cortellini A, Di Padova M, Ficorella C. "Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer. Int J Mol Sci 2018;19:E299. [PMID: 29351242 DOI: 10.3390/ijms19010299] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
608 Moorcraft SY, Smyth EC, Cunningham D. The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therap Adv Gastroenterol 2013;6:381-95. [PMID: 24003339 DOI: 10.1177/1756283X13491797] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
609 Yue B, Cai D, Liu C, Fang C, Yan D. Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer. Mol Ther. 2016;24:2064-2077. [PMID: 27633443 DOI: 10.1038/mt.2016.180] [Cited by in Crossref: 100] [Cited by in F6Publishing: 105] [Article Influence: 16.7] [Reference Citation Analysis]
610 Shiroiwa T, Fukuda T, Tsutani K. Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan. Int J Clin Oncol 2010;15:256-62. [PMID: 20198398 DOI: 10.1007/s10147-010-0045-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
611 Sakamoto Y, Sakaguchi Y, Oki E, Minami K, Toh Y, Okamura T. Surgical outcomes after resection of both hepatic and pulmonary metastases from colorectal cancer. World J Surg. 2012;36:2708-2713. [PMID: 22782440 DOI: 10.1007/s00268-012-1708-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
612 Sartori S, Tombesi P, Di Vece F. Thermal ablation in colorectal liver metastases: Lack of evidence or lack of capability to prove the evidence? World J Gastroenterol 2016; 22(13): 3511-3515 [PMID: 27053843 DOI: 10.3748/wjg.v22.i13.3511] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
613 Hori N, Iwasa S, Hashimoto H, Yanai T, Kato K, Hamaguchi T, Yamada Y, Murakoshi K, Yokote N, Yamamoto H, Shimada Y. Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer. Int J Clin Oncol 2013;18:435-8. [PMID: 22415742 DOI: 10.1007/s10147-012-0398-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
614 Iorio J, Lastraioli E, Tofani L, Petroni G, Antonuzzo L, Messerini L, Perrone G, Caputo D, Francesconi M, Amato MM, Cadei M, Arcangeli G, Villanacci V, Boni L, Coppola R, Di Costanzo F, Arcangeli A. hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients. Transl Oncol 2020;13:100740. [PMID: 32105990 DOI: 10.1016/j.tranon.2020.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
615 Fiorentini G, Sarti D, Aliberti C, Carandina R, Mambrini A, Guadagni S. Multidisciplinary approach of colorectal cancer liver metastases. World J Clin Oncol 2017; 8(3): 190-202 [PMID: 28638789 DOI: 10.5306/wjco.v8.i3.190] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
616 Lin Z, Yang Y, Huang Y, Liang J, Lu F, Lao X. Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis. Mol Clin Oncol 2015;3:959-67. [PMID: 26171215 DOI: 10.3892/mco.2015.572] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
617 Fiala O, Finek J, Buchler T, Matejka VM, Holubec L, Kulhankova J, Bortlicek Z, Liska V, Topolcan O. The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study. Target Oncol 2015;10:549-55. [PMID: 25875421 DOI: 10.1007/s11523-015-0365-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
618 Belardinilli F, Capalbo C, Malapelle U, Pisapia P, Raimondo D, Milanetti E, Yasaman M, Liccardi C, Paci P, Sibilio P, Pepe F, Bonfiglio C, Mezi S, Magri V, Coppa A, Nicolussi A, Gradilone A, Petroni M, Di Giulio S, Fabretti F, Infante P, Coni S, Canettieri G, Troncone G, Giannini G. Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. Front Oncol 2020;10:560. [PMID: 32457828 DOI: 10.3389/fonc.2020.00560] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
619 Uchima Y, Nishii T, Iseki Y, Ishii M, Hiramatsu S, Iwauchi T, Morimoto J, Kosaka K, Tei S, Takeuchi K. Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer. Mol Clin Oncol 2014;2:134-8. [PMID: 24649322 DOI: 10.3892/mco.2013.205] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
620 Yin C, Jiang C, Liao F, Rong Y, Cai X, Guo G, Qiu H, Chen X, Zhang B, He W, Xia L. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther 2014;7:1415-22. [PMID: 25143746 DOI: 10.2147/OTT.S64559] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
621 Stein A, Quidde J, Schröder JK, Göhler T, Tschechne B, Valdix AR, Höffkes HG, Schirrmacher-Memmel S, Wohlfarth T, Hinke A, Engelen A, Arnold D. Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study. BMC Cancer 2016;16:82. [PMID: 26865161 DOI: 10.1186/s12885-016-2113-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
622 Marques I, Araújo A, Mello RA. Anti-angiogenic therapies for metastatic colorectal cancer: Current and future perspectives. World J Gastroenterol 2013; 19(44): 7955-7971 [PMID: 24307789 DOI: 10.3748/wjg.v19.i44.7955] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
623 Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2017;14:235-246. [PMID: 27922044 DOI: 10.1038/nrclinonc.2016.171] [Cited by in Crossref: 239] [Cited by in F6Publishing: 236] [Article Influence: 39.8] [Reference Citation Analysis]
624 Tanigawa K, Maekawa M, Kiyoi T, Nakayama J, Kitazawa R, Kitazawa S, Semba K, Taguchi T, Akita S, Yoshida M, Ishimaru K, Watanabe Y, Higashiyama S. SNX9 determines the surface levels of integrin β1 in vascular endothelial cells: Implication in poor prognosis of human colorectal cancers overexpressing SNX9. J Cell Physiol 2019;234:17280-94. [PMID: 30784076 DOI: 10.1002/jcp.28346] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
625 Li S, Xu K, Gu D, He L, Xie L, Chen Z, Fan Z, Zhu L, Du M, Chu H, Zhang Z, Wu Y, Ni M, Wang M. Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer. J Gastroenterol 2019;54:939-49. [PMID: 30923916 DOI: 10.1007/s00535-019-01571-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
626 Nasti G, Piccirillo MC, Izzo F, Ottaiano A, Albino V, Delrio P, Romano C, Giordano P, Lastoria S, Caracò C. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer. 2013;108:1566-1570. [PMID: 23558891 DOI: 10.1038/bjc.2013.140] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
627 Zeng T, Fang X, Lu J, Zhong Y, Lin X, Lin Z, Wang N, Jiang J, Lin S. Efficacy and safety of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis 2021. [PMID: 34716473 DOI: 10.1007/s00384-021-04028-z] [Reference Citation Analysis]
628 Roselló S, Borrás R, Cervantes A. Maintenance with single agent bevacizumab fails to improve disease-control in metastatic colorectal cancer. Hepatobiliary Surg Nutr 2018;7:395-8. [PMID: 30498717 DOI: 10.21037/hbsn.2018.08.02] [Reference Citation Analysis]
629 Li W, Quan YY, Li Y, Lu L, Cui M. Monitoring of tumor vascular normalization: the key points from basic research to clinical application. Cancer Manag Res 2018;10:4163-72. [PMID: 30323672 DOI: 10.2147/CMAR.S174712] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
630 Spolverato G, Ejaz A, Azad N, Pawlik TM. Surgery for colorectal liver metastases: The evolution of determining prognosis. World J Gastrointest Oncol 2013; 5(12): 207-221 [PMID: 24363829 DOI: 10.4251/wjgo.v5.i12.207] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
631 Juez I, Rubio C, Figueras J. Multidisciplinary approach of colorectal liver metastases. Clin Transl Oncol. 2011;13:721-727. [PMID: 21975333 DOI: 10.1007/s12094-011-0722-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
632 Leach MR, Lau D, La Marca F, Park P. Outcomes after surgery for spinal metastasis of colorectal origin: case series. Asian Spine J 2014;8:267-72. [PMID: 24967040 DOI: 10.4184/asj.2014.8.3.267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
633 Fiorentini G, Aliberti C, Sarti D, Coschiera P, Tilli M, Mulazzani L, Giordani P, Graziano F, Gonzalez AM, Marcos RG, Mugnoz FG, Cantore M, Ricci S, Catalano V, Mambrini A. Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. World J Gastrointest Oncol 2015; 7(6): 47-54 [PMID: 26090075 DOI: 10.4251/wjgo.v7.i6.47] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
634 Suzuki N, Hazama S, Nagasaka T, Tanioka H, Iwamoto Y, Negoro Y, Yamauchi M, Kobayashi M, Okuda H, Fujishima N, Nishimura T, Yamanaka N, Toyota K, Mori Y, Nakagami Y, Shimokawa M, Nagano H, Okajima M. Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study). Int J Clin Oncol 2019;24:1223-30. [PMID: 31144145 DOI: 10.1007/s10147-019-01473-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
635 Kurebayashi H, Goi T, Shimada M, Tagai N, Naruse T, Nakazawa T, Kimura Y, Hirono Y, Yamaguchi A. Prokineticin 2 (PROK2) is an important factor for angiogenesis in colorectal cancer. Oncotarget 2015;6:26242-51. [PMID: 26317645 DOI: 10.18632/oncotarget.4385] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
636 Sagawa T, Sato Y, Hirakawa M, Hamaguchi K, Fukuya A, Okamoto K, Miyamoto H, Muguruma N, Fujikawa K, Takahashi Y, Takayama T. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab. Sci Rep 2020;10:19815. [PMID: 33188279 DOI: 10.1038/s41598-020-76756-1] [Reference Citation Analysis]
637 Fan Q, Lv W, Xu Y, Dong Y, Xiang Z, Wang J. Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis. Curr Pharm Des 2020;26:3171-86. [PMID: 32067605 DOI: 10.2174/1381612826666200218095932] [Reference Citation Analysis]
638 Wang W, Zhao LR, Lin XQ, Feng F. Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer. World J Gastroenterol 2014; 20(21): 6691-6697 [PMID: 24914397 DOI: 10.3748/wjg.v20.i21.6691] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
639 Awada G, de Azambuja E, Awada A. Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients. Expert Opin Drug Metab Toxicol 2017;13:1205-15. [PMID: 29088977 DOI: 10.1080/17425255.2017.1398733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
640 Suetsugu T, Matsuhashi N, Takahashi T, Tanahashi T, Matsui S, Imai H, Tanaka Y, Yamaguchi K, Yoshida K. Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases. Mol Clin Oncol 2018;9:587-91. [PMID: 30546885 DOI: 10.3892/mco.2018.1742] [Reference Citation Analysis]
641 Gu Y, Yu H, Hao C, Martin TA, Hargest R, He J, Cheng S, Jiang WG. NHERF1 regulates the progression of colorectal cancer through the interplay with VEGFR2 pathway. Oncotarget 2017;8:7753-65. [PMID: 27999191 DOI: 10.18632/oncotarget.13949] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
642 Noel MS. Biologics in bowel cancer. J Gastrointest Oncol 2017;8:449-56. [PMID: 28736632 DOI: 10.21037/jgo.2017.05.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
643 Aridome K, Mori SI, Baba K, Yanagi M, Hamanoue M, Miyazono F, Tokuda K, Imamura H, Ogura Y, Kaneko K, Kijima F, Maemura K, Ishigami S, Natsugoe S. A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients. Mol Clin Oncol 2016;4:393-8. [PMID: 26998290 DOI: 10.3892/mco.2015.724] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
644 Glynne-Jones R, Chau I. Neoadjuvant therapy before surgical treatment. EJC Suppl 2013;11:45-59. [PMID: 26217113 DOI: 10.1016/j.ejcsup.2013.07.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
645 Gherman A, Căinap C, Constantin AM, Cetean S, Căinap SS. Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab. Clujul Med 2017;90:377-84. [PMID: 29151784 DOI: 10.15386/cjmed-745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
646 Meyerhardt JA, Tepper JE, Venook AP. Special Series: Advances in GI Cancer. J Clin Oncol 2015;33:1717-20. [PMID: 25918284 DOI: 10.1200/JCO.2015.60.8661] [Cited by in Crossref: 8] [Article Influence: 1.1] [Reference Citation Analysis]
647 Wang H, Huang L, Gao P, Zhu Z, Ye W, Ding H, Fang L. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial. BMJ Open 2020;10:e030738. [PMID: 32051297 DOI: 10.1136/bmjopen-2019-030738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
648 Pohl M, Reinacher-schick A, Schmiegel W. Palliative endoscopic and chemotherapeutic treatment. Eur Surg 2010;42:287-98. [DOI: 10.1007/s10353-010-0571-9] [Reference Citation Analysis]
649 Tang PA, Moore MJ. Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Therap Adv Gastroenterol. 2013;6:459-473. [PMID: 24179482 DOI: 10.1177/1756283x13502637] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
650 Cha JJ, Lee H, Kim M, Kang J, Song H, Kim MG, Lee JH. Immobilized DNA aptamers used as potent attractors for vascular endothelial cell: in vitro study of female rat. Biosci Rep 2020;40:BSR20182444. [PMID: 31930392 DOI: 10.1042/BSR20182444] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
651 Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010;102:80-6. [PMID: 19920817 DOI: 10.1038/sj.bjc.6605417] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
652 Rossi L, Veltri E, Zullo A, Zoratto F, Colonna M, Longo F, Mottolese M, Giannarelli D, Ruco L, Marchetti P. Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. Onco Targets Ther. 2013;6:1761-1769. [PMID: 24348051 DOI: 10.2147/ott.s43828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
653 Feo L, Polcino M, Nash GM. Resection of the Primary Tumor in Stage IV Colorectal Cancer: When Is It Necessary? Surg Clin North Am. 2017;97:657-669. [PMID: 28501253 DOI: 10.1016/j.suc.2017.01.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
654 Scarpelli M, Rampurwala M, Eickhoff J, Carmichael L, Heideman J, Binger K, Kolesar J, Perlman S, Harrow K, Dukart G, Liang C, Jeraj R, Liu G, Bruce JY. Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. Cancer Chemother Pharmacol 2018;82:211-9. [PMID: 29802443 DOI: 10.1007/s00280-018-3599-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
655 Azzariti A, Porcelli L, Brunetti O, Del Re M, Longo V, Nardulli P, Signorile M, Xu JM, Calabrese A, Quatrale AE, Maiello E, Lorusso V, Silvestris N. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World J Gastroenterol 2016; 22(27): 6287-6295 [PMID: 27468218 DOI: 10.3748/wjg.v22.i27.6287] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
656 Nakajima H, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Negoro Y, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okuyama H, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Moriwaki T. Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment. Front Oncol 2021;11:688709. [PMID: 34211856 DOI: 10.3389/fonc.2021.688709] [Reference Citation Analysis]
657 Bednarsch J, Jara M, Lock JF, Malinowski M, Pratschke J, Stockmann M. Noninvasive diagnosis of chemotherapy induced liver injury by LiMAx test--two case reports and a review of the literature. BMC Res Notes 2015;8:99. [PMID: 25889706 DOI: 10.1186/s13104-015-1055-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
658 Wu D, Zhao Y, Fu S, Zhang J, Wang W, Yan Z, Guo H, Liu A. Seleno-short-chain chitosan induces apoptosis in human breast cancer cells through mitochondrial apoptosis pathway in vitro. Cell Cycle 2018;17:1579-90. [PMID: 29895197 DOI: 10.1080/15384101.2018.1464845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
659 Byun JH, Ahn JB, Kim SY, Kang JH, Zang DY, Kang SY, Kang MJ, Shim BY, Baek SK, Kim BS, Lee KH, Lee SI, Cho SH, Sohn BS, Kim S, Hwang IG, Nam EM, Seo BG, Oh SC, Lee MA, Lee SC, Hong JH, Park YS. The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. Korean J Intern Med 2019;34:165-77. [PMID: 29172407 DOI: 10.3904/kjim.2016.348] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
660 Zhu J, Wang L, Liu F, Pan J, Yao Z, Lin Y, Yang Y, Xiong X, Li K, Yang Y, Zhang Y, Chu X, Pan Y, Zhang H. Targeting PELP1 Attenuates Angiogenesis and Enhances Chemotherapy Efficiency in Colorectal Cancer. Cancers 2022;14:383. [DOI: 10.3390/cancers14020383] [Reference Citation Analysis]
661 Aparo S, Goel S. Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. Crit Rev Oncol Hematol 2012;83:47-58. [PMID: 21944740 DOI: 10.1016/j.critrevonc.2011.08.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
662 Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:57-84. [PMID: 26753006 DOI: 10.1177/1758834015614530] [Cited by in Crossref: 203] [Cited by in F6Publishing: 194] [Article Influence: 33.8] [Reference Citation Analysis]
663 Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR Jr, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2013;24:220-5. [PMID: 22898037 DOI: 10.1093/annonc/mds245] [Cited by in Crossref: 101] [Cited by in F6Publishing: 89] [Article Influence: 10.1] [Reference Citation Analysis]
664 Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Gao L, Hsu Y, Xu Y, Ferry D, Alberts SR, Wainberg ZA. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol. 2016;27:2196-2203. [PMID: 27765757 DOI: 10.1093/annonc/mdw423] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 11.5] [Reference Citation Analysis]
665 Yanmaz MT, Guner SI, Satılmıs B, Akyol H, Aydın MA. Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion. Med Oncol 2014;31:276. [PMID: 25294426 DOI: 10.1007/s12032-014-0276-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
666 Bai L, Wang F, Li ZZ, Ren C, Zhang DS, Zhao Q, Lu YX, Wang DS, Ju HQ, Qiu MZ, Wang ZQ, Wang FH, Xu RH. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis. Medicine (Baltimore) 2016;95:e4531. [PMID: 28002313 DOI: 10.1097/MD.0000000000004531] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
667 Nakanishi R, Kitao H, Kiniwa M, Morodomi Y, Iimori M, Kurashige J, Sugiyama M, Nakashima Y, Saeki H, Oki E, Maehara Y. Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication. Sci Rep 2017;7:16969. [PMID: 29208954 DOI: 10.1038/s41598-017-17282-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
668 Bai L, Wang F, Zhang DS, Li C, Jin Y, Wang DS, Chen DL, Qiu MZ, Luo HY, Wang ZQ, Li YH, Wang FH, Xu RH. A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer. Sci Rep 2015;5:17717. [PMID: 26620439 DOI: